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Résumé 
 
Introduction : La prévention de la mort de cellules cardiaques contractiles suite à un 
épisode d'infarctus du myocarde représente le plus grand défi dans la récupération de la fonction 
cardiaque. On a démontré à maintes reprises que l'ocytocine (OT), l'hormone bien connue pour 
ses rôles dans le comportement social et reproductif et couramment utilisée dans l’induction de 
l’accouchement, diminue la taille de l'infarctus et améliore la récupération fonctionnelle du 
myocarde blessé. Les mécanismes de cette protection ne sont pas totalement compris. 
Objectif : Étudier les effets d'un traitement avec de l'ocytocine sur des cardiomyocytes 
isolés en utilisant un modèle in vitro qui simule les conditions d'un infarctus du myocarde. 
Méthodes : La lignée cellulaire myoblastique H9c2 a été utilisée comme modèle de 
cardiomyocyte. Pour simuler le dommage d'ischémie-reperfusion (IR), les cellules ont été 
placées dans un tampon ischémique et incubées dans une chambre anoxique pendant 2 heures. 
La reperfusion a été accomplie par la restauration du milieu de culture régulier dans des 
conditions normales d'oxygène. L'OT a été administrée en présence ou en absence d'inhibiteurs 
de kinases connues pour être impliquées dans la cardioprotection. La mortalité cellulaire a été 
évaluée par TUNEL et l'activité mitochondriale par la production de formazan pendant 1 à 4 
heures de reperfusion. La microscopie confocale a servie pour localiser les structures cellulaires. 
Résultats : Le modèle expérimental de l'IR dans les cellules H9c2 a été caractérisé par 
une diminution dans la production de formazan (aux alentours de 50 à 70 % du groupe témoin, p 
< 0.001) et par l'augmentation du nombre de noyaux TUNEL-positif (11.7 ± 4.5% contre 1.3 ± 
0.7% pour le contrôle). L'addition de l'OT (10-7 a 10-9 M) au commencement de la reperfusion a 
inversé les effets de l'IR jusqu'aux niveaux du contrôle (p < 0.001). L'effet protecteur de l'OT a 
été abrogé par : i) un antagoniste de l'OT ; ii) le knockdown de l'expression du récepteur à l'OT 
induit par le siRNA ; iii) la wortmannin, l'inhibiteur de phosphatidylinositol 3-kinases ; iv) 
iv 
 
 
KT5823, l'inhibiteur de la protéine kinase dépendante du cGMP (PKG); v) l'ODQ, un inhibiteur 
du guanylate cyclase (GC) soluble, et A71915, un antagoniste du GC membranaire. L'analyse 
confocale des cellules traitées avec OT a révélé la translocation du récepteur à l'OT et la forme 
phosphorylée de l'Akt (Thr 308, p-Akt) dans le noyau et dans les mitochondries. 
Conclusions : L'OT protège directement la viabilité des cardiomyocytes, lorsqu'elle est 
administrée au début de la reperfusion, par le déclenchement de la signalisation du PI3K, la 
phosphorylation de l'Akt et son trafic cellulaire. La cytoprotection médiée par l'OT implique la 
production de cGMP par les deux formes de GC. 
 
Mots-clés : Ocytocine, cardioprotection, ischémie-reperfusion myocardiale 
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Abstract 
 
Introduction: The prevention of the death of contractile cardiac cells following an episode 
of myocardial infarction represents the largest challenge in the recovery of myocardial function. 
Oxytocin, the hormone best known for its roles in reproduction and social behaviour and used 
commonly for the induction of parturition, has been repeatedly demonstrated to decrease the 
infarct size and to ameliorate the functional recovery of the injured myocardium. The 
mechanisms for this protection are incompletely understood. 
Objective: To study the effects of oxytocin treatment on isolated cardiomyocytes using an 
in vitro model simulating the conditions of a myocardial infarction. 
Methods: The cardiomyoblastic cell line H9c2 was used as a model of cardiomyocyte. 
For IR injury, the cells were placed in ischemic buffer and incubated in an anoxic chamber for 2 
hours. Reperfusion was achieved by restoring cell media under normoxic conditions. OT was 
administered in the presence or absence of enzyme inhibitors. Cell death was evaluated by 
TUNEL and mitochondrial activity by formazan production during 1-4 hours of reperfusion. 
Confocal microscopy served for localization of cell structures. 
Results. The experimental model of IR in H9c2 cells was characterized by decreased 
formazan production (at the range of 50-70% of normoxic control, p < 0.001) and by the 
increased number of TUNEL-positive nuclei (11.7±4.5 vs. 1.3±0.7% in normoxic control). The 
addition of OT (10-7 to 10-9 M) at the onset of reperfusion reversed the effects of IR to the control 
levels (p < 0.001). The protective effect of OT was abrogated by: i) an OT antagonist, OTA and 
siRNA-mediated OT receptor knockout; ii) the phosphatidylinositol 3-kinases inhibitor 
wortmannin; iii) the cGMP-dependent protein kinase (PKG) inhibitor, KT5823. Soluble 
guanylate cyclase (GC) inhibitor ODQ and particulate GC antagonist A71915 only partially 
blocked the protective effects of OT. Confocal analysis of OT-treated cells revealed translocation 
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of OT receptor and the phosphorylated form of Akt (Thr 308, p-Akt) into the nucleus and 
mitochondria. 
Conclusions: OT directly protects cardiomyocyte viability if administered at the onset of 
reperfusion by triggering signaling of Pi3K, Akt phosphorylation and its cellular trafficking. OT-
mediated cytoprotection involves cGMP production by both forms of GC. 
 
Keywords : Oxytocin, cardioprotection, myocardial ischemia - reperfusion.  
 
 
vii 
 
 
Table of Contents 
 
Résumé .................................................................................................................................... iii 
Abstract .....................................................................................................................................v 
List of Tables .......................................................................................................................... xii 
List of Figures........................................................................................................................ xiii 
List of Abbreviations ............................................................................................................... xv 
Acknowledgements .................................................................................................................. xx 
Dedication ...............................................................................................................................xxi 
 
I. INTRODUCTION .............................................................................................................1 
I.1. Myocardial ischemia - reperfusion injury ..........................................................................1 
I.1.1. Pathophysiology of ischemia - reperfusion injury .......................................................1 
I.1.2. Cardioprotection by ischemic pre- and postconditioning .............................................4 
I.1.3. Cardioprotective signaling involved in pre- and postconditioning ...............................5 
I.1.3.1. Reperfusion injury salvage kinase (RISK) Pathway .............................................6 
I.1.3.1.1. Pi3K/Akt .......................................................................................................6 
I.1.3.1.2. eNOS-cGMP/PKG ........................................................................................8 
I.1.3.2. Survivor activating factor enhancement (SAFE) pathway ....................................9 
I.1.3.3. Mitochondria as the target for IRI and postconditioning ..................................... 10 
I.1.3.3.1. Mitochondrial ATP-sensitive K+ channels (mitoKATP) and PKC................ 10 
I.1.3.3.2. Signalosome hypothesis of cardioprotective signaling ................................. 11 
I.2. Oxytocin System ............................................................................................................. 12 
I.2.1. Oxytocin receptors ................................................................................................... 14 
I.2.2. OT/OTR in cytoprotective signaling ......................................................................... 15 
I.2.3. OT as a cardioprotective hormone ............................................................................ 16 
I.2.4. Atrial natriuretic peptide ........................................................................................... 21 
I.2.4.1. ANP in myocardial ischemia-reperfusion ........................................................... 22 
viii 
 
 
I.2.5. Cardiovascular effects of OT and OTR gene knockouts ............................................ 23 
I.2.5.1. OT knockout ...................................................................................................... 23 
I.2.5.2. OTR knockout ................................................................................................... 24 
I.3. The use of isolated cardiomyocytes for the study of cardioprotective signaling: advantages 
and limitations. ...................................................................................................................... 24 
I.4. Hypothesis and Aims ...................................................................................................... 26 
I.4.1. Hypothesis ............................................................................................................... 26 
I.4.2. Aims ........................................................................................................................ 26 
 
II. MATERIALS AND METHODS ....................................................................................... 27 
II.1. Cell Culture ................................................................................................................... 27 
II.1.1. H9c2 myoblastic cell line from rat embryonic heart ................................................. 27 
II.1.2. Isolation of rat adult ventricular cardiomyocytes ..................................................... 28 
II.2. Simulated Ischemia - Reperfusion .................................................................................. 30 
II.3. Cell viability and DNA fragmentation ............................................................................ 33 
II.4. Antagonists and Inhibitors ............................................................................................. 34 
II.5. siRNA-mediated knockdown of OTR ............................................................................ 36 
II.6. Immunofluorescence and confocal microscopy .............................................................. 37 
II.6.1. Image capture and processing .................................................................................. 39 
II.7. Intracellular ROS production ......................................................................................... 40 
II.8. Western Blot .................................................................................................................. 40 
II.8.1. Protein extraction .................................................................................................... 40 
II.8.2. Protein quantification .............................................................................................. 41 
II.8.3. Electrophoretic migration of protein samples........................................................... 41 
II.8.3.1. Sample preparation ........................................................................................... 41 
II.8.3.2. Preparation of SDS polyacrylamide gels ........................................................... 42 
II.8.4. Transfer of proteins to nitrocellulose membrane ...................................................... 44 
II.8.4.1. Ponceau red transfer verification, blocking and incubation with antibodies ....... 44 
II.9. Statistical Analysis ......................................................................................................... 46 
ix 
 
 
 
III. RESULTS.......................................................................................................................... 47 
III.1. Standardization of Experimental Conditions ................................................................. 47 
III.1.1. H9c2 cells are a good model of cardiomyocyte in simulated ischemia-reperfusion 
experiments. ...................................................................................................................... 47 
III.1.2. Viability of H9c2 cells ........................................................................................... 49 
III.1.3. Simulated ischemia-reperfusion (IR) protocol ........................................................ 50 
III.1.4. siRNA-mediated knockdown of OTR .................................................................... 51 
III.1.4.1. Transfection efficiency determined using AF555-labelled negative control 
siRNA sequence ............................................................................................................ 51 
III.1.4.2. Confirmation of OTR knockdown ................................................................... 54 
III.2. Oxytocin protects cardiomyocyte viability .................................................................... 55 
III.2.1. Pre-treating H9c2 cells with oxytocin protects them from death after simulated 
ischemia-reperfusion. ........................................................................................................ 55 
III.2.2. Oxytocin protects cell viability optimally if administered at the onset of reperfusion
 .......................................................................................................................................... 58 
III.2.2.1. OT administered at reperfusion protects optimally at concentrations ranging 
from 1 - 250 nM ............................................................................................................ 61 
III.3. The protection afforded by OT is mediated by oxytocin receptor .................................. 62 
III.3.1. OTA concentration-dependently blocks the protective effect of OT. ...................... 62 
III.3.2. OTR knockdown reverses the protective pattern observed by OT treatment on cell 
death ................................................................................................................................. 63 
III.3.3. A high concentration of vasopressin, administered at reperfusion, exerts a mild 
protection of metabolic viability in H9c2 cells. .................................................................. 64 
III.3.4. An antagonist to vasopressin receptors V1a and V2 protects viability only in the 
absence of oxytocin ........................................................................................................... 65 
III.4. Mechanisms of oxytocin-induced cytoprotection .......................................................... 67 
III.4.1. Oxytocin decreases the formation of reactive oxygen species (ROS) in 
cardiomyocytes exposed to IR. .......................................................................................... 67 
x 
 
 
III.4.2. OT treatment in normoxic conditions causes an increase in intracellular ROS 
production. ........................................................................................................................ 68 
III.4.3. OT preconditioning of H9c2 cells protects them from doxorubicin-induced 
cytotoxicity ....................................................................................................................... 70 
III.4.4. Pi3K-Akt-eNOS signaling is involved in OT-mediated protection from simulated 
ischemia - reperfusion ....................................................................................................... 72 
III.4.4.1. Pi3K inhibitor Wortmannin blocks the protective effect of Oxytocin ............... 72 
III.4.4.2. OT stimulation causes Akt phosphorylation (Thr308) and co-localization with 
mitochondria in the perinuclear region ........................................................................... 73 
III.4.4.3. OT treatment causes eNOS phosphorylation (Ser1177) and nuclear co- 
localization with p-Akt (Thr308). .................................................................................. 80 
III.4.5. The cGMP/PKG pathway mediates OT-induced cardioprotection .......................... 83 
III.4.5.1. cGMP-dependent protein kinase (PKG) activity .............................................. 83 
III.4.5.2. Guanylate cyclase activity ............................................................................... 84 
 
IV. DISCUSSION .................................................................................................................... 87 
IV.1. Experimental Models.................................................................................................... 88 
IV.1.1. H9c2 cells are a good in vitro model of oxytocin signaling in cardiomyocyte 
ischemia - reperfusion ....................................................................................................... 88 
IV.2. OT protects cardiomyocyte survival ............................................................................. 89 
IV.2.1. OT preconditioning directly protects cardiomyocyte survival................................. 89 
IV.2.2. OT exerts an optimal protective effect if administered only at reperfusion ............. 90 
IV.2.3. The protection induced by OT is mediated by OTR ............................................... 91 
IV.2.3.1. OTR knockdown reverses the protective pattern seen by OT treatment. .......... 92 
IV.3. Mechanisms of OT - induced cardiomyocyte protection ............................................... 93 
IV.3.1. OT prevents the intracellular formation of reactive oxygen species after 1 and 2 
hours of reperfusion ........................................................................................................... 93 
IV.3.2. OT treatment under normoxic conditions causes a short - lived burst in ROS 
production ......................................................................................................................... 93 
xi 
 
 
IV.3.3. OT protects from doxorubicin - induced mitochondrial toxicity ............................. 94 
IV.4. Signalisation involved in OT-mediated cardiomyocyte protection ................................ 95 
IV.4.1. Pi3K/Akt signaling ................................................................................................ 95 
IV.4.2. OT causes phosphorylated Akt (Thr308) to co-localize with mitochondria in or 
around the nucleus ............................................................................................................. 96 
IV.4.3. OT mediates cardioprotection through eNOS phosphorylation and cGMP-PKG 
signaling. ........................................................................................................................... 97 
IV.5. Signalosome hypothesis ............................................................................................. 100 
 
V. CONCLUSIONS............................................................................................................... 102 
 
Bibliography ......................................................................................................................... xxii 
xii 
 
 
List of Tables 
 
Table 1. Oxytocin-mediated cardioprotection in myocardial ischemia - reperfusion................... 19 
Table 2. Reagents employed in cell culture................................................................................ 27 
Table 3. Cell culture media used for ARVCM isolation and culture ........................................... 29 
Table 4. Krebs-Henseleit (KH) buffer used for perfusion, with and without Ca2+....................... 29 
Table 5. Perfusion Digestion Solution prepared in KH buffer .................................................... 30 
Table 6. Incubation Digestion Solution prepared in KH buffer .................................................. 30 
Table 7. Ischemic Buffer composition ....................................................................................... 31 
Table 8. Antagonists and Inhibitors used ................................................................................... 35 
Table 9. siRNA sequences used ................................................................................................. 37 
Table 10. Solutions used in immunofluorescent staining ........................................................... 38 
Table 11. Commercial products used in immunofluorescence .................................................... 38 
Table 12. Antibodies and sera used for immunofluorescence ..................................................... 39 
Table 13. RIPA buffer composition ........................................................................................... 41 
Table 14. 5X Denaturing reducing Laemmli protein loading dye ............................................... 42 
Table 15. Solutions used in SDS-PAGE preparation .................................................................. 43 
Table 16. 10X Electrophoresis Buffer solution .......................................................................... 43 
 
xiii 
 
 
List of Figures 
 
Figure 1. Pathophysiology of Myocardial Ischemia - Reperfusion injury .....................................3 
Figure 2. Neurophysin - Oxytocin. ............................................................................................ 13 
Figure 3. Schematic model of the human OTR spanning the membrane. ................................... 14 
Figure 4. Simulated Ischemia - Reperfusion (IR) protocol. ........................................................ 32 
Figure 5. H9c2 cells express cardiomyocyte proteins and receptors of the oxytocin system. ...... 48 
Figure 6. Formazan production is linearly related to H9c2 seeding density up to 20,000 cells/cm2.
 .......................................................................................................................................... 49 
Figure 7. Experimental simulated ischemia-reperfusion (IR) protocol. ...................................... 50 
Figure 8. H9c2 viability after various times under hypoxic conditions. ...................................... 51 
Figure 9. Optimization of siRNA-mediated knockdown of OTR. .............................................. 53 
Figure 10. siRNA-mediated knockdown of OTR  ...................................................................... 54 
Figure 11. Preconditioning cardiomyocytes with 1 nM OT beginning 15 minutes prior to the 
onset of ischemia and maintained throughout the simulated ischemia-reperfusion (IR) 
experiment prevents cell death. .......................................................................................... 57 
Figure 12. OT protects cardiomyocyte viability optimally if administered exclusively at 
reperfusion. ....................................................................................................................... 60 
Figure 13. Concentration -response of oxytocin administered at reperfusion. ............................. 61 
Figure 14. OT antagonist OTA concentration-dependently abolishes the protective effect of OT 
treatment at reperfusion. .................................................................................................... 62 
Figure 15. OTR signaling is necessary for OT-induced protection of viability. .......................... 64 
Figure 16. The role of vasopressin system in OT-mediated protection. ...................................... 66 
Figure 17. OT treatment prevents ROS formation following simulated ischemia-reperfusion. ... 68 
Figure 18. Intracellular ROS production after stimulation of H9c2 cells with OT. ..................... 70 
Figure 19. OT partially protects from doxorubicin - induced H9c2 cell death. ........................... 71 
xiv 
 
 
Figure 20. The phosphatidylinositol-3-OH kinase (Pi3K)-Akt pathway inhibitor, Wortmannin  
blocks OT-mediated protection in a concentration - dependent manner. ............................. 73 
Figure 21. OT treatment causes Akt phosphorylation and accumulation in and around the nuclei 
of H9c2 cells. .................................................................................................................... 75 
Figure 22. OT treatment causes p-Akt phosphorylation in a structure within the nuclei. ............ 76 
Figure 23. OT treatment causes p-Akt phosphorylation in a structure within the nuclei. ............ 77 
Figure 24. OT treatment causes p-Akt phosphorylation in a structure around the nuclei............. 78 
Figure 25. H9c2 cells subjected to hypoxia and treated with OT at reperfusion period display Akt 
phosphorylation and p-Akt and Cox IV translocation in the perinuclear region. ................. 79 
Figure 26. OT causes p-eNOS accumulation in the nuclei of H9c2 cells. ................................... 81 
Figure 27. Co-localization of phosphorylated eNOS and phosphorylated Akt in H9c2 cells 
stimulated with 62.5 nM of OT. ......................................................................................... 82 
Figure 28. cGMP-dependent protein kinase (PKG) inhibitor KT-5823 blocks the protective effect 
of OT (62.5 nM) treatment at reperfusion. ......................................................................... 84 
Figure 29. Inhibition of cGMP production blocks the protection induced by OT treatment at 
reperfusion. ....................................................................................................................... 86 
Figure 30. Proposed protective signaling triggered by OT in cardiomyocytes. ........................... 99 
Figure 31. OTR signalosome hypothesis. ................................................................................ 101 
  
xv 
 
 
List of Abbreviations 
 
A: Adenine 
AF: Alexa Fluor 
AMP: adenosine monophosphate 
AMPK: AMP-activated protein kinase  
ANOVA: analysis of variance 
ANP: atrial natriuretic peptide 
APS: ammonium persulfate  
AR: adrenergic receptors 
ARVCM: Adult rat ventricular cardiomyocytes 
ATP: adenosine triphosphate 
AVP: arginine vasopressin 
Bcl-2: B-cell lymphoma 2 
BNP: brain natriuretic peptide 
BSA: bovine serum albumin 
C - cytosine 
Cai : intracellular calcium 
CaM: Ca2+- Calmodulin 
CaMKK: CaM kinase kinase 
cGMP: cyclic guanosine 3', 5’-monophosphate 
CHD: coronary heart disease 
CM: cardiomyocyte 
CM-H2DCFDA: 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester 
CNP: C-type natriuretic peptide 
DAG: 1,2-diacylglycerol 
DAPI: 4',6-diamidino-2-phenylindole 
DMEM: Dulbecco's modified eagle medium 
xvi 
 
 
DMSO: dimethylsulfoxide 
DNA: deoxyribonucleic acid 
Dox: Doxorubicin 
EDTA: ethylenediaminetetraacetic acid 
ER : endoplasmic reticulum 
Erk1/2 : extracellular-regulated kinases 1 and 2 
FBS: fetal bovine serum 
eNOS: endothelial nitric oxide synthase 
G : guanine 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase  
GLUT: glucose transporter 
GPCR: G-protein coupled receptor 
GSK: glycogen synthase kinase 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HR: heart rate 
IgG: immunoglobulin G 
IL : interleukin 
i.p. : intraperitoneal 
IP3 : inositol trisphosphate 
IPC: ischemic pre-conditioning 
IR: simulated ischemia - reperfusion 
IRAP: insulin regulated aminopeptidase 
i.v.: intravenous 
JAK: Janus kinase 
KRH: Krebs-Ringer HEPES  
KT-5823 : (2,3,9,10,11,12-hexahydro 10R-methoxy-2,9-dimethyl-1-oxo-9S,12R-epoxy-1H-
diindolo[1,2,3-fg:3’,2’,1’-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, methyl ester) 
L: liter 
LSM: confocal laser scanning microscope 
xvii 
 
 
LV: left ventricular 
MAP: mean arterial pressure 
MAPK: mitogen-activated protein kinase 
MI: myocardial infarction 
min: minute(s) 
mitoKATP: mitochondrial ATP-sensitive K+ channels 
mPTP: mitochondrial permeability transition pore;  
mRNA: messenger RNA 
mTOR: mammalian target of rapamycin 
MTS: [3-(3,5-dimethylthialzol-2-yl)-5-(3 carboxymethoxypheny)-2-(4-sulphophenyl)-2H-
tetrazolium] 
NAC: N-acetylcysteine  
NHE: Na+/H+ exchanger 
NCE: Na+/Ca2+ exchanger 
NO: nitric oxide 
NP: natriuretic peptide 
NPR: natriuretic peptide receptor  
O2: molecular oxygen 
ODQ : 1H-1,2,4- oxadiazolo [4,3-a] quinoxalin-1-one 
OT : oxytocin 
OTA: oxytocin antagonist 
OTKO: oxytocin knockout 
OTR: oxytocin receptor 
OTRKO: oxytocin receptor knockout 
p-Akt: phosphorylated Akt 
p-eNOS: phosphorylated eNOS 
PBS: phosphate buffered saline 
PC: ischemic postconditioning 
PDK-1: phosphoinositide-dependent kinase 1  
xviii 
 
 
pGC: particulate guanylate cyclase 
Pi3K phosphatidylinositol-3-kinase 
PIP2 : phosphatidyl inositol 4,5-bisphosphate 
PIP3: phosphatidylinositol-3,4,5-triphosphate  
PKC: protein kinase C 
PKG: cGMP-dependent protein kinase 
PLB: phospholamban 
PLC-β: phospholipase C type β  
PMSF : phenylmethanesulphonylfluoride 
RAAS: renin-angiotensin-aldosterone system 
RIPA: radio immunoprecipitation assay 
RISK: reperfusion injury salvage kinases 
RNA: ribonucleic acid 
ROS: reactive oxygen species 
rpm: revolutions per minute 
RT: room temperature 
RT-PCR: Real time polymerase chain reaction 
s.c.: subcutaneous 
SDS: sodium dodecyl sulfate 
SERCA: sarcoplasmic reticulum Ca2+ ATPase  
SEM: standard error 
sGC: soluble guanylate cyclase 
IR: simulated ischemia - reperfusion 
siRNA: small interfering RNA 
STAT: signal transducer and activator of transcription  
T: thymine 
TBS: tris buffered saline 
TCA: trichloroacetic acid  
TEMED: tetramethylethylenediamine 
xix 
 
 
TGF: transforming growth factor 
TNF: tumor necrosis factor 
Tris: trisaminomethane 
TUNEL: Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling 
V1a: vasopressin receptor type 1a 
VEGF: vascular endothelial growth factor 
  
xx 
 
 
Acknowledgements 
 
I would like to thank my supervisors, Dr. Marek Jankowski and Dr. Jolanta Gutkowska 
for so generously accepting me into their laboratory and for their continued support and 
encouragement throughout the course of my master's project. I thank them for sharing their 
knowledge and enthusiasm with me. Thank you for believing in me and inspiring me to improve 
myself.  
I would also like to thank all the members of the laboratory, in particular Christophe 
Fadainia, Dominique Genest and Dr. Eric Plante, whose encouragement and moral support have 
been invaluable to me; Dr. Bogdan Danalache and Dr. Alexandre Popov for so generously 
sharing their incredible expertise, and Dr. Ahmed Menaouar and Julien Durand for both moral 
and technical support.  
I extend a special thank you to my family, including my new Canadian family, whose 
love and support have allowed me to thrive. Lastly I thank my loving husband, whose constant 
love, patience and inspiration mean the world to me. 
 
 
  
xxi 
 
 
Dedication 
 
I dedicate this work to my parents, whose love, inspiration and support have always 
encouraged me to aim high and pursue my dreams. I am eternally grateful.  
 
 

1 
 
 
I. INTRODUCTION 
I.1. Myocardial ischemia - reperfusion injury  
Coronary heart disease (CHD) is the leading cause of death in the world1. A serious 
manifestation of CHD is cardiac ischemia, caused by the interruption of blood flow to the cardiac 
tissue and an inadequate O2 supply to the heart. Acute ischemia as in the case of acute 
myocardial infarction (MI) is treated by the rapid restoration of blood flow through reperfusion 
strategies. Although reperfusion is necessary for cardiac rescue, the abrupt restoration of blood 
flow results in ischemia-reperfusion injury of the myocardium2,3. The ensuing cell death is 
triggered by several factors including cellular and mitochondrial calcium overload, oxidative 
stress, reduction in nitric oxide (NO) production, and inflammatory response. The loss of 
contractile cardiac cells, cardiomyocytes, remains the largest challenge to functional recovery 
from an episode of acute MI1. Even with current reperfusion strategies, 10% of acute MI patients 
die and 25% progress to heart failure1, with 7 million deaths each year directly attributable to MI 
around the world4.  
 
I.1.1. Pathophysiology of ischemia - reperfusion injury  
Mitochondrial damage is a major factor triggering the loss of myocardial cells5. Under normal 
physiological conditions myocardial tissue produces more than 90% of its ATP by mitochondrial 
oxidative phosphorylation6. During ischemia cardiomyocytes rely on anaerobic glycolysis, 
leading to intracellular acidosis7,8. This acidosis causes a stimulation of the activity of the 
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sarcolemmal Na+/H+ exchanger (NHE-1) to extrude excess H+ ions from the cytosol, with 
concomitant Na+ overload of the cytosol8. The excess of intracellular Na+ in turn causes an 
increase in intracellular Ca2+ due to the action of the Na+/Ca2+ exchanger (NCE)8. The depletion 
of ATP during ischemia prevents the activity of pumps such as the Na+/K+ ATPase, as well as 
active Ca2+ excretion which prevents the re-establishment of normal cellular ionic 
homeostasis5,8,9. The intracellular Ca2+ overload causes calpain activation, apoptotic cascades, 
mitochondrial permeability transition pore (mPTP) opening and hypercontracture. However, the 
intracellular acidosis present during ischemia causes a decrease in the affinity of troponin to Ca2+ 
and phosphofructokinase, which hinders the functioning of the myocardial contractile apparatus7 
preventing hypercontracture. Similarly, cell death during ischemia is prevented as a lower 
intracellular pH inhibits the formation of the mitochondrial permeability transition pore.  
Lethal reperfusion injury arises from the rapid normalization of physiological conditions after a 
period of ischemia. As the extracellular pH normalizes it causes a massive efflux of H+ from the 
cell and influx of Na+, causing the Na+/Ca2+ exchanger to operate in reverse mode and further 
increase intracellular Ca2+ overload. Furthermore, there is an increase in reactive oxygen species 
(ROS) production in the first minutes of reperfusion as O2 is re-introduced into damaged 
mitochondria9. High intracellular [Ca2+] and ROS trigger the opening of the mitochondrial 
permeability transition pore (mPTP)5,10.  The mPTP is a large conductance pore that forms on the 
mitochondrial membrane, releases mitochondrial proteins into the cytosol and triggers cell 
death11 by apoptosis and necrosis. Sustained opening of mPTP is considered the irreversible 
point in the commitment of a cell to death10. 
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Figure 1. Pathophysiology of Myocardial Ischemia - Reperfusion injury. During ischemia, 
the reduced O2 supply causes an increase in the rate of glycolysis, generating H+ and lactate and 
decreasing intracellular pH (pHi). The Na+/H+ exchanger, NHE, overloads the cytosol with Na+ 
as the excess H+ are extruded, causing the reversal of the Na+/Ca2+ exchanger, which extrudes 
excess Na+ but overloads the cytosol with Ca2+. The use of ATP-dependent pumps is limited by 
lack of ATP. However, the intracellular acidosis inhibits mPTP opening. During reperfusion, 
abrupt restoration of the extracellular pH causes an even more pronounced efflux of H+ from the 
cell, aggravating further the mechanisms outlined above. As the pHi is normalized, and a ROS 
burst is created as O2 is reintroduced, the inhibition of mPTP opening is lifted and lethal 
reperfusion injury can arise.  
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I.1.2. Cardioprotection by ischemic pre- and postconditioning  
A significant reduction in infarct size is observed when the myocardium is exposed to brief 
intermittent periods of ischemia and reperfusion, both at a time prior to ischemia, known as 
ischemic preconditioning (IPC), or immediately after reperfusion, known as ischemic 
postconditioning (PC). For the first time, Murry et al. reported that four cycles of brief 
intermittent ischemia before the onset of a sustained episode of ischemia followed by reperfusion 
reduced infarct size to 25% of that seen in control animals12. They termed this phenomenon 
ischemic preconditioning (IPC) and much work has been devoted ever since to identify the 
mechanisms involved in this phenomenon. Intracellular signaling pathways that are activated 
during IPC and create a conditioned phenotype are responsible for cell protection and the 
reduction in infarct size13. Adenosine, bradykinin and opioids acting via their respective G-
protein coupled receptors (GPCRs) can mimic the IPC response, which is thought to converge on 
protein kinase C (PKC) activation, likely via the opening of mitochondrial ATP-sensitive K+ 
channels14 and prevention of mPTP opening13. The signaling cascades recruited by IPC appear to 
be active during the reperfusion phase and mediate IPC-induced protection at reperfusion15.  
More recently, a cardioprotective effect of performing an intermittent ischemia protocol at the 
onset of reperfusion following a prolonged ischemic episode in anesthetized dogs was reported 
by Zhao et al.16. They termed this effect ischemic postconditioning (PC) and it was shown to be 
equally effective as IPC at reducing final infarct size. Approximately 50% of the final infarct size 
is believed to be preventable through conditioning strategies1. 
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Two mechanisms of cardioprotection by PC have been proposed: passive mechanisms, in which 
the protection results from a gradual restoration of the pre-ischemic conditions rather than an 
abrupt reperfusion, and active, in which cardioprotective signaling mechanisms are triggered 
within the cardiomyocytes17. Active mechanisms include the recruitment and activation of 
kinase-mediated signaling pathways within the injured cardiomyocytes, such as the RISK and 
SAFE pathways (see section I.1.4. below).  
 
I.1.3. Cardioprotective signaling involved in pre- and postconditioning  
IPC is believed to act by activating pro-survival kinases at reperfusion15,18. Several signaling 
pathways have been shown to be activated by PC, and inhibitors of key kinases in these 
pathways can block the protective effect of IPC and PC. The reperfusion injury salvage kinase 
(RISK) pathway includes pro-survival kinases such as phosphoinositide 3-kinases (Pi3K)/Akt, 
AMP-activated protein kinases (AMPK) and extracellular signal-regulated kinases 1 and 2 
(Erk ½), whose signalisation is thought to converge on the activation of cGMP-dependent 
protein kinase (PKG) and protein kinase C (PKC) ε, causing the inhibition of prolonged mPTP 
opening8. Similarly, the survivor activating factor enhancement (SAFE) pathway involving Janus 
kinase (JAK) and signal transducer and activator of transcription (STAT) signaling can provide 
protection separately from the RISK pathway8. The degree of crosstalk between the RISK and 
SAFE pathways is presently unclear, but both are believed to ultimately protect mitochondrial 
function19. The pharmacological manipulation of these pathways represents a more clinically - 
applicable alternative to ischemic conditioning20.  
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I.1.3.1. Reperfusion injury salvage kinase (RISK) Pathway 
I.1.3.1.1. Pi3K/Akt 
Pro-survival kinases known to be involved in PC include phosphatidylinositol 3-kinases (Pi3K), 
which causes the phosphorylation and activation of Akt8. Pi3Ks are a family of intracellular 
signal-transducing lipid kinases with a wide variety of roles in the regulation of cellular 
processes. Three classes of Pi3K (Class I, II and III) have been identified based on the specificity 
of the lipid substrate they phosphorylate21.  
Akt kinase, also known as protein kinase B, is known to be a critical kinase at the core of cellular 
signal integration in survival, growth and proliferation22. Akt activity is modulated by its 
phosphorylation status at residues Thr308 and Ser47323. Accordingly, Akt activity is regulated 
through the activity of intracellular phosphatases and kinases that can directly or indirectly alter 
its phosphorylation status. 
Upon a variety of stimuli including GPCR activation, class I Pi3Ks phosphorylate 
phosphatidylinositol-4,5-biphosphate (PIP2) and convert it to phosphatidylinositol-3,4,5-
triphosphate (PIP3) at the inner surface of the plasma23 and nuclear24 membranes. PIP3 binds 
intracellular enzymes with a pleckstrin homology (PH) domain25, such as Akt and 
phosphoinositide-dependent kinase 1 (PDK-1). PH domains are conserved protein sequences of 
approximately 100 amino acids which are present in a wide range of proteins and mediate their 
interaction with other intracellular components such as proteins and lipids26,27. The interaction of 
PIP3 with Akt and PDK-1 allows for the PDK-1-mediated phosphorylation and activation of Akt 
at Thr30823. For full activation, Akt must also be phosphorylated at a second residue, Ser473, 
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which is thought to be mediated at the plasma membrane by mammalian target of rapamycin 
(mTOR) protein complex 228. Upon activation, Akt accumulates in different cellular 
compartments, including mitochondria29,30 and nuclei31,32.  
Akt phosphorylation and activation reduces cardiomyocyte death from ischemia-reperfusion 
injury and regulates glycogen synthesis, glucose transport, glycolysis, protein synthesis, cell 
enlargement, mitochondrial integrity and cell death28,33. However, studies demonstrating 
negative effects of constitutive and sustained active Akt expression in cardiomyocytes, such as 
hypertrophy, suggested that there could be an important spatial and temporal regulation of Akt 
activation28. 
It was recently discovered that Pi3K activation resulted in a rapid accumulation of Akt in the 
mitochondria in neuroblastoma and embryonic kidney cell lines, preventing the release of 
apoptotic proteins from the mitochondria34. It appears that translocation of phosphorylated 
(activated) Akt to the mitochondria preserves mitochondrial integrity35. In mice hearts, 
translocation of phosphorylated Akt from the cytosol to the mitochondria was associated with 
ATP-dependent mitochondrial K+ channel (mitoKATP) opening36. Similarly, insulin stimulated 
phosphorylation and translocation of Akt to the mitochondria of mice cardiomyocytes37, and 
constitutively active mitochondria-targeted Akt over-expression prevented cell death in rat 
neonatal cardiomyocytes29. A mitochondria-targeted constitutively active Akt protected 
mitochondrial integrity as indicated by the prevention of the loss of mitochondrial membrane 
electrochemical gradient in cardiomyocytes exposed to H2O2 or Doxorubicin29. 
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There exist several known mitochondrial targets for Akt such as Bcl-2 family members22 and 
hexokinase II38 whose phosphorylation by Akt favours survival. Other downstream targets of 
Akt are nitric oxide (NO) synthase (NOS)22 isoforms (such as mitochondrial NOS)39, which 
become active upon Akt - mediated phosphorylation, as well as glycogen synthase kinase (GSK) 
and caspase-9, both of which become inactive through phosphorylation by Akt30. 
 
I.1.3.1.2. eNOS-cGMP/PKG 
Activation of the cGMP/PKG pathway plays a critical role in the pro-survival signaling triggered 
by IPC and PC. The second messenger cyclic guanosine 3', 5’-monophosphate (cGMP) is 
generated by soluble or particulate guanylyl cyclases (sGC or pGC). pGC are natriuretic peptide 
receptors (NPR), whereas sGC is a cytoplasmic heterodimeric haemoprotein activated by nitric 
oxide (NO) and carbon monoxide (CO). The subcellular localization of cGMP generation and 
accumulation plays a role in determining its effect40.  
An important mediator of the effects of cGMP is cGMP-dependent protein kinase (PKG). PKG 
inhibits NHE activity41, delaying normalization of intracellular acidosis during reperfusion which 
is unfavourable for mPTP opening. Other downstream targets of PKG include the opening of 
mitoKATP14. Inhibition of PKG activity with inhibitor KT-5823 blocks the cardioprotective effect 
of insulin42, of B-type natriuretic peptide and of NO43. 
Additionally, nitric oxide (NO) production is known to be a mediator of IPC19, and exogenous 
NO can induce pharmacological postconditioning44 independently of PKG activity through S-
9 
 
 
nitrosylation of protein thiol groups45. The phosphorylation-based activation of eNOS (at residue 
Ser1177) is known to be involved in the protection by IPC, PC and pharmacological 
conditioning19. 
 
I.1.3.2. Survivor activating factor enhancement (SAFE) pathway 
Activation of the JAK/STAT pathway is necessary for the infarct-reducing effects of ischemic 
preconditioning46 and plays important roles in postconditioning8. In the canonical model of 
JAK/STAT signaling the binding of cytokines, such as tumor necrosis factor alpha (TNFα), to 
plasma membrane cytokine receptors causes dimerization of the receptors. JAK proteins 
associated to these receptors trans-phosphorylate each other upon dimerization and become 
activated, allowing them to phosphorylate the cytoplasmic part of the associated cytokine 
receptor at specific tyrosines. STAT proteins can then specifically bind the phosphotyrosine 
motifs on the receptors, and get phosphorylated by JAKs. Phosphorylated STAT proteins 
dimerize and translocate to the nucleus, where they regulate the transcription of target genes47.   
TNFα activation in the heart is necessary for the induction of cardioprotection by IPC, and TNFα 
treatment mimics IPC independently of RISK pathway activation48. TNFα is believed to trigger 
signaling through the activation of STAT-3 proteins48 which cause the inactivating 
phosphorylation of glycogen synthase kinase 3β (GSK3β) and Bad, a pro-apoptotic protein, as 
well as an increase in Bcl-2 and a decrease in bax expression48.  Cardioprotective STAT-3 
signaling confers cellular protection in a timeframe that indicates actions independently of but 
concomitant to its transcription factor activities48.  
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I.1.3.3. Mitochondria as the target for IRI and postconditioning 
As mentioned above, cardiomyocytes are highly reliant on oxidative phosphorylation. The 
mitochondrial permeability transition pore (mPTP) is a large conductance channel of unclear 
identity that forms across the mitochondrial membranes, collapses the mitochondrial membrane 
potential and allows for the release of mitochondrial proteins to the cytosol, which trigger 
caspase cascades and cell death8,10. Under normal physiological conditions, the mPTP remains 
closed, and it is well-established that mPTP opening occurs during reperfusion after myocardial 
ischemia11,49. The conditions that favour mPTP opening at reperfusion are a burst in ROS 
production when oxygen is re-introduced into damaged mitochondria, high intracellular and 
intra-mitochondrial Ca2+ levels and the normalization of the intracellular pH, since acidosis 
inhibits its opening8. Since mPTP opening is viewed as the irreversible commitment of a cell to 
death, prevention of its opening is seen as the key endpoint of cardioprotection10. Indeed, mPTP 
prevention is viewed as the effector of pre- and postconditioning10.  
Activation of the reperfusion injury salvage kinases (RISK) pathway at reperfusion is thought to 
prevent mPTP opening8,50. Similarly, the opening of mitochondrial ATP-dependent K+ channels 
(mitoKATP) has been linked to the prevention of mPTP opening, and mitoKATP channels are 
modulated by known cardioprotective kinases of the RISK pathway such as PKG14 and Akt36. 
 
I.1.3.3.1. Mitochondrial ATP-sensitive K+ channels (mitoKATP) and PKC 
The opening of mitoKATP channels causes an influx of K+ and water into the mitochondrial 
matrix, which causes ROS generation by the respiratory complex I and activation of PKC, p38 
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MAPK19 and phosphorylation of phospholamban (PLB) at Ser16, which modulates the 
sarcoplasmic reticulum Ca2+ ATPase (SERCA) and normalizes Ca2+ handling, preventing 
hypercontracture and opening of the mPTP8. The molecular identity of mitoKATP remains 
unclear, but they are known to be causally involved in IPC and PC19. 
 
I.1.3.3.2. Signalosome hypothesis of cardioprotective signaling 
The question remains as to how the activation of cytosolic kinases (such as those in the RISK 
pathway) could rapidly modulate the appearance of the mPTP in the mitochondrial membranes. 
To address this problem, Garlid et al.51,52 proposed the Signalosome hypothesis of 
cardioprotective signaling. This hypothesis proposes that GPCR signaling at the plasma 
membrane results in the caveolar assembly of vesicles containing various kinases, forming 
signaling complexes that are then translocated intracellularly to the mitochondria and 
phosphorylate receptors on the outer mitochondrial membrane. This triggers the phosphorylation 
of a mitochondrial pool of protein kinase C-ε which in turn phosphorylates and opens mitoKATP 
channels51. These signalosomes are formed upon various cardioprotective stimuli, such as IPC, 
PC, bradykinin; they can be isolated and when added to untreated hearts can cause mitoKATP 
opening and prevention of mPTP formation. These 100-140 nm vesicles contain caveolin 3, Akt, 
PKG, eNOS and GC51. 
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I.2. Oxytocin System 
Oxytocin (OT) is a small peptide known to mediate a wide variety of physiological functions, 
both as a hormone and as a neurotransmitter, from childbirth and lactation to socialization and 
appetite modulation53. Clinically, oxytocin analogues are widely used in the induction of labour 
during childbirth and for the prevention of post-partum hemorrhage. Synthetic analogues of 
oxytocin are amongst the most commonly used pharmaceuticals in the world and are listed in the 
World Health Organization's list of essential medications54. 
Initially discovered by Dale in 1906 for its uterotonic and milk ejection effects, OT was the first 
peptide hormone whose structure was elucidated in 195355. OT is highly conserved in all animal 
species with the amino acid sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 and a disulfide 
bridge between Cys residues 1 and 656. In mammals, OT is primarily synthesized in the 
supraoptic and paraventricular nuclei of the hypothalamus. OT is transcribed as a long precursor 
protein, preprooxytocin, of 160-170 amino acid residues. This preprohormone includes the 
signaling peptide and the OT carrier protein neurophysin I which is synthesised from the same 
gene as OT. OT is then processed and transported by neurophysin I to the posterior pituitary and 
stored in neurosecretory granules at high concentrations (0.1 M) until its release into circulation56 
in a pulsatile manner57. The intermediate form of OT is the tri-aminoacid extended OT-Gly-Lys-
Arg (OT-GKR) and has recently been shown to also exert significant biological activity58. 
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Figure 2. Neurophysin - Oxytocin.  Larger ribbon structure depicts neurophysin; stick-and-ball 
structure depicts oxytocin. Taken from Wikimedia Commons.  
 
Traditionally, OT has been considered a female reproductive hormone although the observations 
that OT is released in men and women to the same degree and through the same stimuli have 
revealed OT to be involved in many processes distinct from reproduction in both men and 
women. OT plays a role in the regulation of food intake, stress responses, immune modulation, 
cardiovascular regulation and in complex social behaviours such as bonding and relationship 
maintenance56,59.  
OT is related to a second neurohypophyseal hormone, arginine vasopressin (AVP). AVP is also a 
nonapeptidic hormone differing from OT in residues 3 and 8 (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-
Arg-Gly-NH2). AVP induces vasoconstriction, water retention and corticotrophin release60, 
whereas OT causes natriuresis, vasodilatation, decreases in blood pressure, negative cardiac 
inotropic and chronotropic effects61, and decreases cortisol levels62. 
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I.2.1. Oxytocin receptors 
Only one receptor specific for OT has been discovered so far. This receptor, OTR, is a member 
of the class I family of G protein - coupled receptors (GPCR) with seven trans-membrane 
domains56.  
 
Figure 3. Schematic model of the human OTR spanning the membrane. The amino acid 
residues in black circles have been proposed as OT docking sites, and the red bars represent 
docking sites of OT-GKR. Figure taken from Danalache et al., 201058.  
 
The regulation of OTR expression is species-specific56. OTR expression has been described in a 
variety of tissues and cell types such as myometrial smooth muscle cells, myoepithelial cells of 
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mammary glands, vascular endothelium, kidney epithelium, hypothalamus, anterior pituitary, 
astrocytes, osteoblasts, adipocytes56 and, recently, cardiomyocytes63. Additionally, OT can 
trigger signalisation via vasopressin receptors V1 and V2a but with lower affinity64. 
The OTR gene is composed of a 17 kb region and contains four exons and three introns, one of 
which (intron 3) is believed to be involved in OTR transcriptional suppression. The promoter 
region of the OTR gene contains interleukin response elements as well as estrogen response 
elements in rats, mice and humans56. It is believed that the OTR promoter is constitutively active. 
Introns 1 and 3 are probably involved in methylation-based suppression of OTR expression57. 
OTR, like other GPCRs, undergoes a rapid desensitization upon OT stimulation  (>60% decrease 
in 5-10 minutes of OT stimulation of Hek293 cells) that is based on receptor internalization56. 
OTR is associated to caveolae on the plasma membrane. 
 
I.2.2. OT/OTR in cytoprotective signaling 
OT has been shown to protect various tissues and cell types from ischemia-reperfusion injury. 
After the initial report that OT administration had anti-inflammatory, pro-survival effects on rat 
musculocutaneous flaps65, Tugtepe et al.66 showed that OT, given before the onset of renal  
ischemia and again before reperfusion was started, improved kidney function and decreased 
damage to the tissue and oxidative stress through decreases in neutrophil infiltration and fibrosis. 
Similarly, in a rat model of hepatic ischemia-reperfusion OT (500 µg/kg, i.p.) given 24 and 12 
hours before an ischemic insult and again just prior to the onset of reperfusion alleviated hepatic 
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damage, fibrosis and neutrophil infiltration67. More recently, OT (1 µM administered during the 
ischemic insult) was shown to protect immature hippocampal cell cultures in vitro from loss of 
viability resulting from oxygen-glucose deprivation, and this effect was fully blocked by the use 
of an OT antagonist68. 
 
I.2.3. OT as a cardioprotective hormone 
Following the observation by our laboratory that OT is a cardiovascular hormone63,69, a 
cardioprotective effect of OT has been revealed. OT stimulates release of the cardioprotective 
atrial natriuretic peptide (ANP) from isolated dog atria in an OTR-mediated mechanism that 
appears to be dependent on the action of intrinsic parasympathetic postganglionic neurons63. OT 
was also shown to have transient negative inotropic and chronotropic effects on perfused isolated 
dog right atria in a mechanism independent of ANP release and mediated by nitric oxide (NO) 
production and acetylcholine release at cardiac parasympathetic postganglionic neurons61. 
Ondrejcakova et al. 70 showed for the first time that in isolated rat hearts, a 25 minute perfusion 
with OT preceding the induction of an ischemic insult reduced infarct size by 66% as compared 
with control hearts. In the same study the elimination of the negative chronotropic effect of OT 
by the electrical stimulation of heartbeat eliminated the infarct reduction, which led the authors 
to conclude that OT- induced protection of ischemic myocardium is dependent upon its negative 
chronotropic effects. Kobayashi et al.71 demonstrated in a rabbit model of ACUTE MI that daily 
subcutaneous treatments with OT (10 mg/kg, s.c.) immediately following reperfusion 
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significantly reduced infarct size, had pro-angiogenic and anti-fibrotic effects and increased the 
activation of pro-survival kinases Akt, Erk1/2 and STAT3, as well as eNOS; anti apoptotic Bcl-2 
was up-regulated in the ischemic myocardium following OT treatment, indicating potential anti-
apoptotic effects. Interestingly, Akt, Erk1/2, eNOS and STAT3 have all been previously shown 
to be mediators of cardiac pre- and postconditioning8.  
Further supporting a cardioprotective role for OT, the expression of OT and its receptor was 
strongly induced both in the heart and hypothalamus of ovariectomized and sham-operated rats 
following exercise training, indicating a possible involvement of OT in exercise’s 
cardioprotective effects72, and down-regulated by 40-50% in the injured left ventricle of mice73 
and rats74 following MI. Jankowski et al. found that this down-regulation following MI could be 
reversed by administration of OT (25 ng/kg/h, s.c.) given before the onset of ischemia and during 
one week of reperfusion in a rat model of myocardial infarction74. In the same study, OT was 
revealed to reduce the expression of pro-inflammatory cytokines (TNFα, IL-1β and IL-6) 
produced by MI back to the levels seen in sham-operated rats; OT could also reduce immune cell 
infiltration (especially of neutrophils), induce eNOS production and normalize ANP mRNA 
expression in the scar area, and had pro-proliferative, anti-apoptotic and anti-fibrotic effects on 
injured hearts. OT was found to decrease IL-6 secretion from macrophages and endothelial cells 
in a dose-dependent manner, and to attenuate superoxide production in aortic endothelial and 
smooth muscle cells, monocytes and macrophages75. OT was also shown to induce glucose 
uptake in vitro in neonatal rat cardiomyocytes under conditions of chemical hypoxia by a 
pathway involving Pi3K76.  
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Work by Alizadeh et al.77 showed that the infarct size reduction in the anesthetized rat heart 
induced by a pre-treatment with OT (0.03µg/kg i.p.) 25 minutes prior to ischemia was eliminated 
by the co-treatment with an inhibitor of the opening of mitoKATP channels, which have been 
proposed as the end-effectors of cardioprotective ischemic pre- and postconditioning78. 
Interestingly, the same group found that the protective effects of ischemic preconditioning (IPC) 
were completely eliminated by the administration of an antagonist specific to the OT receptor at 
the start of IPC, suggesting a role for endogenous OT in cardiac ischemic preconditioning79. No 
reports exist on the role of endogenous OT signaling in postconditioning. 
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Table 1. Oxytocin-mediated cardioprotection in myocardial ischemia - reperfusion. 
 
Ref. 
Myocardial 
Infarction 
model 
Ischemia - 
Reperfusion 
Protocol 
Dose and 
mode of OT 
administration 
Timing of 
administration 
Effect 
70 Isolated 
perfused rat 
heart 
25 min 
ischemia; 120 
min reperfusion 
90 µg/L Perfused with OT for 
25 min before ischemia 
 infarct size by 66% (p < 0.01) 
Improved LV functional recovery  
      
71 Rabbit MI 
 
30 min 
ischemia; 2 and 
14 days 
reperfusion 
10 mg/kg/day 
s.c. 
Immediately after 
reperfusion and once 
per day for 5 days after  
MI 
 infarct size,  fibrosis 
Normalized LV diastolic and systolic dimensions, ejection 
fraction, fractional shortening, +dP/dt , heart rate as well as 
systolic and diastolic blood pressure on day 14 post-MI 
Increased activating phosphorylation of anti-apoptotic Akt, 
Stat3, eNOS  and Erk ½ on day 2 and 14 post-MI 
 expression of VEGF, Bcl-2 
 expression of CD-31 positive microvessels in infarct 
border zone 
 
74  
Rat MI 
Partial ischemia 
for 7 days 
25 and 125 
ng/kg/h s.c. 
Prior to ischemia and 
then for 3 to 7 days of 
reperfusion 
 Cell proliferation in infarct one (measured by PCN 
expression) 
 apoptosis,  fibrosis in remote myocardium 
 neutrophil, macrophage and T lymphocyte infiltration 
 inflammatory cytokine TNF and IL-6 
 TGF-β,  ANP and BNP mRNA level 
 
20 
 
 
77,80–
82 
Rat MI 25 min 
ischemia; 120 
min reperfusion 
0.03 mg/kg 
i.v.and 
0.03µg/kg i.p. 
10 or 25 min prior to 
induction of ischemia 
 infarct size to nearly 50% of control 
 severity of ventricular arrhythmias, tachycardia and 
fibrillation 
 CK-MB in blood 
OT effect blocked by:1. mitoKATP blocker 5-
hydroxydecanoate; 2. OTR antagonist; 3. mPTP opener 
atractyloside; 4. NOS inhibitor L-NAME; 5. PKC inhibitor 
chelerythine; 6. ROS scavenger  N-acetylcysteine. 
 
83 Isolated 
perfused rat 
heart 
30 min 
ischemia; 120 
min reperfusion 
10-12 to 10-10 M 5 min prior to 
reperfusion and 
continued for 25 min 
 infarct size,  CK-MB and malondialdehyde at 
concentrations of 810-12, 10-11 and 210-11 M 
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I.2.4. Atrial natriuretic peptide 
Atrial natriuretic peptide (ANP) is a 28 amino acid peptide that was first isolated from atrial 
muscle and identified to elicit potent diuretic and natriuretic effects84. Other natriuretic peptides 
identified include brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). ANP 
and BNP are predominantly synthesized in the heart, CNP in the central nervous system85. Three 
known natriuretic peptide receptors have been identified: natriuretic peptide receptor A (NPR-
A), B, and C. NPR-A and -B act as membrane-bound guanylate cyclases that upon stimulation 
signal intracellularly through the generation of cyclic guanosine monophosphate (cGMP); NPR-
C is considered a clearance receptor because it internalizes and removes natriuretic peptides from 
the circulation85,86. ANP preferentially acts via NPR-A to stimulate cGMP production85.  
ANP is synthesized as a 126 amino acid peptide pro-ANP and stored in dense secretory granules 
in the atria87. ANP secretion is mainly induced by mechanical stretching of the atria88. Cardiac 
ischemia and endothelin also stimulate, whereas NO inhibits, ANP secretion88. Importantly, 
elevated concentrations of oxytocin (10-6 M) have been reported to elicit ANP release from 
isolated perfused female rat hearts63. 
The immediate effect of ANP is to increase diuresis (water excretion) and natriuresis (sodium 
excretion) by inhibiting Na+ and water re-absorption in the kidney, antagonising the effects of the 
renin - angiotensin - aldosterone system (RAAS)85. ANP acts as an endothelium-independent 
vasodilator and inhibits sympathetic nerve activity89. Furthermore, ANP can act as an autocrine 
and paracrine factor and directly stimulate cardiomyocytes mostly through NPR-A signaling85. 
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Treatment of cardiomyocytes with ANP antagonises the hypertrophic response to 
norepinephrine90 and phenylephrine as well as in basal conditions85 via the generation of cGMP.  
The importance of ANP-NPR-A signaling is demonstrated by the lethality of the NPR-A 
knockout in mice, at 6 months of age, due to congestive heart failure or aortic dissection91.  
 
I.2.4.1. ANP in myocardial ischemia-reperfusion 
The action of ANP opposes several detrimental effects of myocardial reperfusion injury. Plasma 
ANP levels are increased in patients with acute MI89, and infusion of ANP in patients with MI 
causes a decrease in plasma concentrations of aldosterone, angiotensin II and endothelin, and 
inhibits cardiomyocyte cell death89. ANP also decreases macrophage and neutrophil-mediated 
inflammation. In isolated cardiomyocytes, ANP causes an elevation of cGMP and the nuclear 
accumulation of phosphorylated Akt31, which is an key kinase with multiple cardioprotective 
effects in the context of myocardial ischemia-reperfusion (see section I.1.3.1.1). ANP has an 
anti-proliferative effect on cardiac fibroblasts86, helping to decrease fibrosis. Treatment of 
isolated hearts with ANP reduced infarct size via the NO - cGMP - mitoKATP pathway and 
significantly improved the post-ischemic recovery of cardiac output and coronary flow85. A 
clinical trial with acute MI patients receiving an intravenous infusion of ANP (0.025µg/kg/min) 
immediately after reperfusion and during 3 days showed a significant decrease of 14.7% in 
infarct size and a 5% improvement in left ventricular ejection fraction 6-12 months after acute 
MI92. 
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I.2.5. Cardiovascular effects of OT and OTR gene knockouts 
Mouse models of both OT and OTR knockout mice have been developed; these mice are viable 
and display no clear developmental changes, but are incapable of nursing their offspring93,94 and 
display clear metabolic changes95–97.  
 
I.2.5.1. OT knockout 
OT-/- (OTKO) mice were developed by Young et al.98 who reported that these mice present a 
mild hypotension. In this initial study baseline heart rate (HR) was unchanged, but intrinsic HR 
(HR following adrenergic and cholinergic blockade) was significantly higher in OTKO mice99. 
Vagal tone did not differ significantly, but OTKO mice showed lower levels of sympathetic 
activity, leading to a higher sympathetic reserve99. OTKO mice presented an increase in 
baroreflex gain99. Furthermore, OTKO mice consume higher quantities of salt, but not water, 
under overnight fluid deprivation100, in normal conditions101, and following fluid depletion 
induced by polyethyleneglycol102. Others found a slight decrease in BP and HR in OTKO 
mice102 and central stimulation with angiotensin II caused a similar increase in BP in both OTKO 
and control groups102. Mean arterial blood pressure (MAP) and heart rate (HR) averages over 24 
hours were significantly lower in OTKO mice; upon induction of chronic shaker stress for 3 and 
7 days, OTKO mice presented an increase in average MAP in OTKO, but not control, mice103. 
Basal levels of plasma corticosterone remained unchanged in OTKO mice compared to control, 
but stress-induced corticosterone increase was less pronounced in OTKO mice103. 
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OTKO mice displayed an unaltered expression level and distribution of oxytocin receptors 
(OTR)104. Vasopressin (AVP) can elicit physiological effect via the activation of OTR. It was 
therefore proposed that the lack of overt deficiencies induced upon knockout of the OT gene 
could be partially compensated by the direct stimulation of OTR by AVP96,104.  
 
I.2.5.2. OTR knockout 
There were no changes to the overall health, sensorimotor functions or anxiety behaviour in 
OTRKO mice94. OTRKO females displayed normal parturition96,105, mating and litter size105, but 
lacked the milk let-down reflex and maternal behaviour96,105, and the pregnant myometrium did 
not contract upon AVP stimulation105. Furthermore, OTRKO mice displayed increased obesity 
with increased white adipose tissue and adipocyte enlargement with no differences in food 
intake, as well as the inability to regulate internal temperatures upon cold exposure96. The 
expression of α2A adrenergic receptors (AR) was markedly increased, while β3 AR expression 
decreased in brown adipose tissue96. 
 
I.3. The use of isolated cardiomyocytes for the study of 
cardioprotective signaling: advantages and limitations  
The myocardium is composed of a variety of cell types, including fibroblasts, endothelial cells, 
vascular smooth muscle and macrophages. Cardiomyocytes represent between 70-80% of the 
myocardial volume; however, the relative number of cardiomyocytes in the myocardium is a lot 
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lower, estimated between 35 and 55% of all cells, with fibroblasts representing up to 27% of 
myocardial cells106. Thus, interventions such as ischemic conditioning are likely to affect the 
variety of cells present in the myocardium, and the cardioprotective phenotype triggered is likely 
the result of the interplay between the different cells' response to protective stimuli4 through 
interactions and paracrine signaling between them. For example, using a transgenic mice model 
that only expressed erythropoietin (EPO) receptor in endothelial and hematopoietic cells, Teng et 
al. reported that the acute infarct-sparing effect of erythropoietin was mediated by endothelial 
cells107. On the other hand, ischemic preconditioning of isolated cardiomyocytes has been 
reported to protect their viability108,109, indicating an endogenous protective response of 
cardiomyocytes independently of other cell types.  
In order to discern the specific intracellular signalisation elicited upon cardiomyocytes by 
cardioprotective stimuli, isolated cardiomyocytes studies are of great importance4. Furthermore, 
isolated cardiomyocytes in culture allow for a detailed study of the intracellular structures 
involved in cardiomyocyte survival in the context of ischemia-reperfusion injury109. 
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I.4. Hypothesis and Aims 
I.4.1. Hypothesis 
1. Oxytocin directly triggers protective signaling in cardiomyocytes during the acute 
phase of ischemia - reperfusion. 
2. This protective signaling is mediated by the interaction of oxytocin with its receptor, 
OTR, that is expressed by cardiomyocytes. 
3. Oxytocin causes the phosphorylation - dependent activation of pro-survival kinases 
involved in cardiomyocyte salvage from ischemia - reperfusion injury, such as those 
termed reperfusion injury salvage kinases (RISK), including Pi3K-Akt and cGMP-
dependent protein kinase, PKG. 
4. Oxytocin also induces protection indirectly through the release of ANP from 
intracellular stores, causing activation of natriuretic peptide receptor A (NPR-A) and 
subsequent cGMP-dependent cardioprotective signaling. 
I.4.2. Aims 
To establish an in vitro model that adequately simulates the damage induced by ischemia - 
reperfusion on isolated cardiomyocytes.  
To study the detailed cellular effects of oxytocin signaling on cardiomyocytes during the acute 
phase of ischemia - reperfusion injury. 
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II. MATERIALS AND METHODS 
II.1. Cell Culture 
II.1.1. H9c2 myoblastic cell line from rat embryonic heart 
Commercially available H9c2 rat embryonic cardiac myoblasts were purchased from ATCC 
and grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% (v/v) 
fetal bovine serum (FBS, GIBCO Lot. 755216) and 1% (v/v) penicillin/streptomycin (Gibco 
15140) at 37°C and 5% CO2 containing 4 mM L-glutamine, 4500 mg/L glucose, 1 mM 
sodium pyruvate, and 1500 mg/L sodium bicarbonate. Cells were subcultured at 70-80% 
confluence to preserve the myoblastic phenotype. 
For the majority of experiments, cells were seeded on the preceding day at a density of 104 
cells/cm2 and allowed to attach overnight. For experiments where conditions required longer 
incubation times (e.g. siRNA treatments for 48 hours), the cells were seeded at 5,000 
cells/cm2 to maintain the confluence below 80%. All cells were maintained in a humidified 
incubator (Sanyo MCO-17AC) at 37°C containing 5% CO2. 
Table 2 summarizes the reagents used in routine care and culture of cells. 
Table 2. Reagents employed in cell culture 
Product Company Reference 
Dulbecco’s modified Eagle medium (DMEM) ATCC 30-2002 (Lot 30201224) 
Fetal Bovine Serum (U.S.) GIBCO 26140 
Penicillin/Streptomycin GIBCO 15140-122 
Trypsin 0.25%/EDTA 0.1% Multicell 325-043-EL 
Dimethyl sulfoxide (DMSO) Sigma D8418 - 100 mL 
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II.1.2. Isolation of rat adult ventricular cardiomyocytes 
Some key experiments were performed on primary cultures of adult rat ventricular 
cardiomyocytes (ARVCMs) in order to validate our use of H9c2 as a model of adult 
cardiomyocyte. A non-perfusion cell isolation procedure (Cellutron #ac-7018) was attempted 
repeatedly, but gave unsatisfactory cell yields and very high mortality of the cardiomyocytes 
in culture. A perfusion - based isolation procedure was followed instead. 
The chest cavity of anesthetized female adult Sprague-Dawley (250-290 g) rats was 
surgically opened; the ascending aorta was cut and cannulised. The heart was then excised, 
the atria were removed with scissors, and the ventricles were perfused with a KH-Ca2+ 
solution at 37°C for 5 min, followed by a 20 minute perfusion (Gemini PC-1 perfusion pump 
controller) with a digestion solution containing collagenase, hyaluronidase and BSA. The 
ventricles were then transferred to a Petri dish containing a second digestion solution, with 
trypsin and DNAse I, cut longitudinally with new blades, and incubated with light agitation 
at 37°C for 10 minutes. Cell suspensions were filtered using a syringe attached to a Swinnex 
filter to remove debris. After a light centrifugation (1 min, 1000 rpm) to separate fibroblasts, 
the remaining cell suspension, containing an assortment of cell types present in the adult 
ventricle, was purified for cardiomyocytes by sequential washes and decanting onto a 10 mL 
cushion of 6% BSA (3 g BSA in 50 mL M199 media). After allowing cells to settle based on 
density, myocytes accumulated at the bottom of the BSA cushion, with non-myocytes present 
in the upper phase. The myocyte phase was re-suspended in M199 media with 10% FBS, 
counted and plated at a density of 105 cells in each well of a laminin-coated 12-well plate 
(25,000 cells/cm2). When necessary, cells were pipetted using cut plastic micropipette tips to 
minimize mechanical damage to the cells.  
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Table 3. Cell culture media used for ARVCM isolation and culture 
Product Concentration Reference 
M199 with Phenol red  Invitrogen 11150 
Sodium bicarbonate 0.026 M Sigma S4019 
HEPES buffer solution 1M 0.02M Sigma H3375 
BSA 0,20% Serologicals FrV, Very low endotoxin. 
Code 81-068-3 
Pen-Strep (10 000U/10 000g) 1.0% Gibco 15140-148 
L-Ascorbic Acid (free-acid) 0.1mM Sigma A-7631 
Creatine 5mM Sigma C-3630 
Carnitine 2mM Sigma C-0283 
Taurine 5mM Sigma T-9931 
FBS  0 or 10% Gibco 26140-079 
 
Table 4. Krebs-Henseleit (KH) buffer used for perfusion, with and without Ca2+ 
Product Final 
Concentration 
Reference 
NaCl (MW 58.44) 118mM ACL S-2838 
KCl (MW 74.6) 4.7mM Fisher Scientific P-217 
MgSO4*7H2O (MW 246.48) 1.19mM Acros Organics 
213115000 
NaHCO3 (MW 84) 25mM Sigma S4019 
Dextrose (MW 180.2) 11mM ACP D-0660 
KH2PO4 (MW 136.1) 1mM Fisher Scientific P-285 
CaCl2 100x  100mM * J.T. Baker 
* only used for KH-Ca2+ at a concentration of 100 mM 
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Table 5. Perfusion Digestion Solution prepared in KH buffer 
Perfusion Digestion Solution Final Concentration Reference 
Collagenase 1 mg/mL Worthington S4B7097 
205u/mg 
Hyaluronidase 0.3 mg/mL Roche 10 106 500 001 
BSA  1 mg/mL Serologicals FrV, Very 
low endotoxin. Code 81-
068-3 
 
Table 6. Incubation Digestion Solution prepared in KH buffer 
 Final Concentration Reference 
DNAse I ≤ 0.13 mg/mL Sigma DN-25 
Trypsin ≤ 0.13 mg/mL Difco 215240 
 
 
II.2. Simulated Ischemia - Reperfusion 
Sub-confluent plates were placed in warm ischemic buffer in a sealed chamber (Billups-
Rothenberg Modular Incubator Chamber, California, USA) saturated with 95% N2 + 5% CO2 
for 2 hours at 37°C. Table 7 presents the composition of the ischemic buffer.  
Figure 4 presents the treatment schedule for the simulated ischemia-reperfusion (IR) 
experiments. After 2 hours of ischemia, the plates were quickly processed and reperfusion of 
all conditions was performed within 3 minutes of the opening of the anoxic chamber. 
Reperfusion was simulated by the replacement of the ischemic buffer with DMEM 
supplemented with 1% FBS with or without oxytocin, under normoxic conditions (5% CO2), 
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and cells were incubated for an additional 1 - 4 hr. Inhibitors and antagonists were provided 
at the induction of ischemia, dissolved in ischemic buffer, and re-administered in the 
reperfusion media (Figure 4). All controls were treated with the appropriate concentrations of 
vehicle. Additionally, OT antagonist OTA was administered 15 minutes prior to the 
induction of ischemia and maintained throughout the experiment. 
 
Table 7. Ischemic Buffer composition 
 Product Concentration (mM) 
NaCl 128 
KCl 5 
MgSO4 0.4 
KH2PO4 0.3 
MgCl2 0.5 
CaCl2 1.3 
HEPES 10 
Na L-Lactate 20 
NaHCO3 4 
pH 6.8 
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Figure 4. Simulated Ischemia - Reperfusion (IR) protocol. Sub-confluent monolayers of 
H9c2 cells were covered in warm ischemic buffer and placed inside an anoxic chamber for 2 
hours at 37°C. The cells were "reperfused" with pre-equilibrated warm DMEM containing 
1% FBS under normal atmospheric oxygen conditions and further incubated for 2 - 4 hours.  
 
 
 
33 
 
 
II.3. Cell viability and DNA fragmentation 
Cell viability was measured by the conversion of the tetrazolium salt MTS [3-(3,5-
dimethylthialzol-2-yl)-5-(3 carboxymethoxypheny)-2-(4-sulphophenyl)-2H-tetrazolium] into 
a formazan product that is soluble in culture medium (Promega CellTiter Aqueous 96 
# G3580) according to manufacturer's instructions. 20 µL of MTS were added to 100 µL cell 
culture medium in each well of a 96-well plate (Corning Costar #3595) where cells were 
grown. Absorbance at 490 nm was measured using a Symantek plate reader. Blank 
absorbance values resulting from the cell-free oxidation of MTS were subtracted from all 
experimental values.  
TUNEL (Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling) assay 
was performed using DeadEnd™ Fluorometric TUNEL System (Cat. No. G3250, Promega, 
Montreal, QC, Canada) according to the manufacturer’s protocol. Briefly, cells were grown 
on poly-L-lysine - treated cover slips in 6 well plates and after the proper treatment, cells 
were fixed with a solution containing 6% formaldehyde and 2% methanol in PBS, pH 7.4, for 
10 min at RT and permeabilized with 0.2% Triton X-100 in PBS, pH 7.4. Cells were 
incubated in the TUNEL reaction mixture for 1hr in the dark at 37°C, washed and mounted 
on Prolong Gold anti-fade reagent with DAPI (Cat. No. P36931, Invitrogen, Montreal, QC, 
Canada). 
Cells were visualized using an inverted light fluorescent microscope (Olympus IX51) and 
images were captured at 10 and 20X magnifications for analysis using a digital charge-
coupled device camera (Q IMAGING #Q23774). The quantification of TUNEL-positive 
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cells as a proportion of total DAPI-stained nuclei was performed using ImageJ software 
particle analysis. 
Oxytocin used in all experiments was purchased from Sigma (06379-1mg) and dissolved at a 
final concentration of 10-3 M in sterile cell culture-grade ddH2O. 
 
II.4. Antagonists and Inhibitors 
As presented in Figure 4, the simulated ischemia - reperfusion (IR) protocol was followed in 
combination with oxytocin treatments. In order to elucidate the signaling pathways affected 
by OT treatment of the cells, different chemical antagonists and inhibitors were employed. 
Table 8 summarizes all receptor antagonists and signaling pathway inhibitors used 
throughout the experiments. 
Antagonists OTA and Conivaptan were applied to cells in DMEM with 1% FBS for 15 
minutes prior to the induction of ischemia, and then added again to the simulated ischemia 
buffer as well as to the reperfusion medium. All inhibitors were initially applied to the cells 
dissolved in the ischemic buffer as well as in the reperfusion medium.  
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Table 8. Antagonists and inhibitors used 
Product Description Reference Structure 
OTA ((d(CH2)51 Tyr(Me)2 Thr4 Orn8 
Tyr-NH29)-Vasotocin)  
Oxytocin antagonist Bachem H-
9405 
 
Conivaptan V1a and V2 
antagonist 
Astellas 
Pharma 
YM-087  
 
Wortmannin Covalent Pi3K 
inhibitor  
Sigma 
W1628 
 
ODQ  
(l’1H-(1,2,4)oxadiazolo[4,3-
a]quinoxalin-1-one) 
Soluble Guanylate 
Cyclase inhibitor 
 
 
A71915 (H-Arg-Cys-β-
cyclohexyl-Ala-Gly-Gly-Arg-Ile-
Asp-Arg-Ile-D-Tic-Arg-Cys-NH2 
Trifluoroacetate salt ) 
ANP antagonist Bachem 
H3048 
Arg-Cys-β-Cha-Gly-Gly-Arg-Ile-
Asp-Arg-Ile-D-Tic-Arg-Cys-
NH2 (Amidation of C-terminal 
cysteine; D-Tic- D-3-
carboxyisoquinoline; alanine 
residue is β cyclohexylalanine 
(Cha)) 
KT-5823 (2,3,9,10,11,12-hexahydro 
10R-methoxy-2,9-dimethyl-1-oxo-
9S,12R-epoxy-1H-diindolo[1,2,3-
fg:3’,2’,1’-kl]pyrrolo[3,4-
i][1,6]benzodiazocine-10-carboxylic 
acid, methyl ester) 
PKG Inhibitor Sigma 
K1388 
 
Doxorubicin Antitumor 
antibiotic 
Sigma 
D1515 
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II.5. siRNA-mediated knockdown of OTR 
Two different siRNA sequences were used to knockdown OTR expression in order to 
minimize potential off-target effects of each sequence. The final OTR siRNA concentration 
was used at 5 nM; of which 2.5 nM corresponded to each one of the two sequences targeting 
OTR (i.e., 5 nM siOTR = 2.5 pmol sequence 1 + 2.5 pmol sequence 2 in 1mL medium). 
Table 9 presents the siRNA sequences used in all knockdown experiments.  
A negative control (scrambled) sequence labelled a with red fluorescent Alexa Fluor 555 tag 
was selected as a transfection control in order to visualize siRNA incorporation. A positive 
control sequence (All Stars Cell Death #SI04939025) targeting genes essential for cell 
survival was also used to 1) obtain additional visual confirmation of the transfection 
efficiency and 2) in combination with the TUNEL experiments as a positive control for cell 
death. 
H9c2 cells were plated in 24-well plates and shortly after plating (<1hr), transfection 
complexes containing siRNA sequences and transfection reagent (1.25 % v/v to obtain 
0.25%v/v final)  were added to the cells to a final concentration of 5 nM siRNA. Positive and 
negative control sequences were used in each experiment to monitor transfection efficiency. 
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Table 9. siRNA sequences used 
siRNA  Reference Target Sequence Final 
concentration  
Oxytocin 
Receptor 
Rn_Oxtr_7 
SI03106894 
5'-GTGGAGCGTTTGGGACGTCAA-3' 2.5 nM 
Oxytocin 
Receptor 
Rn_Oxtr_6 
SI03054527 
5'-CAAGGCCTACGTCACATGGAT-3' 2.5 nM 
Negative 
Control 
AF555 
AllStars Neg. 
siRNA AF555 
1027286 
Proprietary - not disclosed 5 nM 
Positive 
Control 
Ctrl_AllStars_3 
SI04939025 
Proprietary - not disclosed 5 nM 
HiPerfect 
Transfection 
reagent 
301705 NA 0.25% v/v 
 
II.6. Immunofluorescence and confocal microscopy 
The fluorescently-labelled secondary antibodies were used to study the intracellular 
signalisation triggered upon OT treatment. In these experiments, round glass cover slips were 
placed in each well of a 12-well plate, UV-sterilized for 1 hr and coated with 0.5 mL sterile 
poly-L-lysine solution for 5 minutes at room temperature, after which they were rinsed with 
sterile dH2O and allowed to dry for at least 2 hr. Alternatively, UV-sterilized poly-lysine 
treated glass slides were used in combination with the flexiPERM tissue culture inserts. H9c2 
cells were plated at a density of 5 x103 cells/cm2 on the poly-lysine treated cover slips or 
glass slides. After treatments, cells were fixed with a solution containing 3% formaldehyde 
and 1% methanol in PBS, pH 7.4, for 10 min at RT or overnight at 4°C. Slides were then 
blocked in a solution containing non-immune 5% serum of the host of the secondary 
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antibody. Primary antibody dilutions were applied according manufacturer's instructions at 
room temperature for 2 hr or overnight at 4°C in antibody incubation buffer and covered with 
parafilm. Slides were washed 3X in washing buffer and secondary antibodies conjugated to 
fluorescent dye were applied for 1 hr at RT in the dark. Slides were washed and mounted on 
Prolong Gold anti-fade reagent with DAPI.  
Table 10. Solutions used in immunofluorescent staining 
Solution Description 
Wash Buffer (PBS-GSA) 1X DPBS (Gibco #14190) with 10 mM 
glycine and 0.2% NaN3. 
Permeabilization solution PBS-GSA with 0.5% Triton X-100 
Blocking solution PBS-GSA containing 5% serum of the host 
animal of the secondary antibody used 
Antibody incubation buffer PBS-GSA with 1% BSA 
 
Table 11. Commercial products used in immunofluorescence 
Product Company Reference 
Round glass cover slips, #1.5, 18 mm  Warner 
Instruments 
CS-18R15 (Cat. 64-0714) 
Poly-lysine coated glass microscope 
slides 
Thermo Scientific P4981-001 
FlexiPerm 8 and 12 wells Sarstedt 94.6032.039; 94.6011.438 
Poly-L-Lysine 0.01% solution Sigma P4832 
TissuFix (6% formaldehyde, 2% 
Methanol solution) 
Chaptec NA 
ProLong Gold anti-fade reagent with 
DAPI 
Invitrogen P36931 
Glycine BioShop GLN001.5 
Triton X-100 Sigma T-8787 
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Table 12. Antibodies and sera used for immunofluorescence 
Antibody Host Company Ref. 
OTR (N-19) Goat polyclonal Santa Cruz Sc-8103 
OTR Rabbit Sigma O4389 
V1a Goat Santa Cruz Sc-18096 
GATA4 (G4) Mouse monoclonal Santa Cruz Sc-25310 
Troponin T Mouse monoclonal Abcam Ab27217 
p-Akt (Thr 308) C31E5E Rabbit Cell Signaling 2965S 
Cox IV Mouse Abcam 14744 
p-eNOS Mouse BD Pharmigen 612392 
Normal Goat IgG Goat Santa Cruz Sc-2028 
Normal Rabbit IgG Rabbit Santa Cruz sc-2027 
Normal Mouse IgG Mouse Santa Cruz sc-2025 
Anti mouse Alexa Fluor 568 Goat Invitrogen A11004 
Anti rabbit Alexa Fluor  488 Donkey Invitrogen A21206 
Anti-rabbit Alexa Fluor 488 Goat Invitrogen A11008 
Anti goat Alexa Fluor  568 Donkey Invitrogen A11057 
Normal Donkey serum Donkey Millipore  S30 
Normal Rabbit serum Rabbit GIBCO 16120-099 
Normal Goat serum Goat GIBCO 16210-064 
Normal Mouse serum Mouse Invitrogen 10410 
 
II.6.1. Image capture and processing 
Slides were observed using an inverted microscope (Olympus IX51) and images were 
captured using a digital charge-coupled device camera (Q IMAGING #Q23774).  
Confocal microscopy was performed using a Zeiss LSM 510-META confocal microscope 
equipped with a Laser line Argon 488 nm, HeNe 543 nm and diode 405 nm. Captured images 
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were analyzed with Zen2011 software. Appropriate training in the use of the confocal 
microscope, as well as additional imaging sessions were hired at an hourly fee from the 
McGill Anatomy and Cell Biology Confocal Microscopy facility.  
 
II.7. Intracellular ROS production 
Cells were seeded on 96-well plates with black walls (Nunc # 165305) and allowed to attach 
overnight. The cells were then incubated with the CM-H2DCFDA probe in warm KRH buffer 
at 37°C for 30 minutes, washed and returned to normal growth conditions in the presence and 
absence of OT. Fluorescence was monitored at the indicated times using a fluorescence plate 
reader set at excitation 485/20 nm, emission 528/20 nm. 
 
II.8. Western Blot 
II.8.1. Protein extraction 
Plates containing monolayers of H9c2 cells were placed on ice and washed 2X with ice-cold 
PBS, gently so as to not detach the cells. 100µL of RIPA lysis buffer containing protease and 
phosphatase inhibitors were added per 100-mm Petri plate and cells were scraped with a cell 
scraper (Sarstedt 83.1830) and transferred to pre-chilled Eppendorf tubes kept on ice. The 
samples were vortexed every 5 minutes for 30 minutes while kept on ice. Two sonications of 
10 seconds each were performed and the samples were centrifuged at 12,000 rpm at 4°C for 
20 minutes. The supernatant was recovered, an aliquot taken for protein quantification and 
the remainder kept at -80°C until use.  
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Table 13. RIPA buffer composition 
Ingredient Concentration Reference 
NaCl 150 mM ACP S-2838 
Triton X - 100 1% v/v Sigma T-8787 
Na deoxycholate (C24H39NaO4) 0.5 % w/v Sigma D6750 
SDS 0.1% w/v Invitrogen 15525-017 
Tris 50 mM Invitrogen 15504-020 
Protease/phosphatase inhibitors  ZmTech Scientifique I208052 
 
 
II.8.2. Protein quantification 
The protein concentration in the samples was measured using the Bradford method, in which 
the dye Coomasie Blue binds to the positive amine groups in solution through ionic 
interactions. This interaction stabilizes the dye in a conformation which absorbs light of 595 
nm. The absorbance of the solution is linearly related to the amount of protein in solution up 
to 2 mg/mL. A BSA standard curve ranging from 40 µg/mL to 200 µg/mL was prepared 
using the same buffer as used to extract the protein.  
 
II.8.3. Electrophoretic migration of protein samples 
II.8.3.1. Sample preparation 
After protein quantification, the samples were prepared for electrophoresis by diluting each 
one to the same final concentration (50µg protein/mL) with 5X Laemmli and water to obtain 
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150 µL of each sample. (ie, 150 µL loading sample = 30 µL Laemmli 5X + x µL sample + 
(120-x) µL water). The concentrations were equalized in order to load on the gel the same 
volume in each well. The samples were then boiled in a water bath for 5 min. 
 
Table 14. 5X Denaturing reducing Laemmli protein loading dye 
Component Concentration Reference 
1.5 M Tris HCl 300 mM Invitrogen 15504-020 
Glycerol 50% Sigma G6279 
β-mercaptoethanol 5% Gibco 21985-023 
SDS 10% Invitrogen 15525-017 
1% Bromophenol Blue 0.050% Sigma B-5525 
pH 6.2 (adjust)  
 
 
II.8.3.2. Preparation of SDS polyacrylamide gels 
Separation gels were prepared at different acrylamide concentrations (7.5, 10 or 12.5%) and 
cast on BioRad glass supports with 0.5 mL isobutanol poured gently on top of each gel. After 
polymerisation of the separation gel, a 4% acrylamide stacking gel was cast on top of the 
separation gel. All gels had a final width of 1.0 mm. 
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Table 15. Solutions used in SDS-PAGE preparation 
Solution Use 
1.5 M Tris pH 8.8 Separation gel 
0.5 M Tris pH 6.8 Stacking gel 
Acrylamide stock (29% acrylamide, 1% bisacrylamide) Invitrogen 15512-023 
SDS 10% Invitrogen 15525-017 
APS (0.1 g/mL)* Sigma A3678 
TEMED Sigma T-8133 
* APS solution freshly prepared each time. 
 
Gels were mounted on an electrophoresis apparatus (Bio-Rad Mini Protean Tetra Cell). The 
chamber was filled with electrophoresis running buffer (192 mM glycine, 25 mM Tris, 1% 
SDS, pH 8.3) and the gels were cast inside. 5 to 10 µg protein in 1X Laemmli buffer were 
loaded in each well. All wells contained the same final volume to favour a straight migration. 
Volumes were adjusted with 1X Laemmli as required. 
The electrophoresis chamber containing the loaded gels was placed at 4°C and connected to a 
power source. The electrophoresis was carried out at 80V for 30 minutes and then at 120V 
for 1-3 hours until the band of interest reached the middle of the gel. 
Table 16. 10X Electrophoresis Buffer solution 
Component Concentration  
Glycine 1920 mM 
Tris 250 mM 
SDS 1.0% 
pH 8.3 
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II.8.4. Transfer of proteins to nitrocellulose membrane 
A transfer buffer was freshly prepared containing 192 mM glycine, 25 mM Tris, 20% 
methanol and kept cold (4°C) until use. For larger (>100kDa) proteins, 1 mL of SDS 10% 
was added to 3L of transfer buffer to facilitate the transfer. When the electrophoresis was 
done, the gels were cut and placed in transfer buffer to equilibrate, along with the 
membranes, for 15 minutes at room temperature. Three pieces of blotting paper, cut to the 
size of the membrane were soaked in transfer buffer and placed one by one on the anode (+) 
side of the transfer cassette. The membrane was carefully placed on top of the blotting paper, 
then the gel on top of the membrane and three pieces of blotting paper. Any bubbles formed 
were carefully rolled out with the use of a glass pipette rolled along the blotting paper. The 
transfer was carried out at 20V for 1.5 hr. 
 
II.8.4.1. Ponceau red transfer verification, blocking and incubation with 
antibodies 
All incubations of the membranes were performed with light agitation on a shaker. The 
membranes were placed in Ponceau red stain (aqueous solution containing 0.2% w/v 
Ponceau red and 0.75% w/v trichloroacetic acid) for 2-3 minutes and rinsed with distilled 
water until protein bands were visible against a white background. This step allows for the 
verification of an equal transfer of proteins onto the membrane. 
The membranes were then washed 3X with tris buffered saline (25 mM tris, 150 mM NaCl, 
pH 7.4) containing 0.1% Tween 20 (TBS-T; Tween 20 from Sigma #P1379). Non-specific 
binding sites for the antibody were blocked by incubating the membrane for 1 hr at room 
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temperature in a solution, prepared in TBS-T, containing 5% fat-free milk or 2% blocking 
powder (ECL Advance blocking reagent) when phosphorylated proteins were the subject of 
the investigation. 
After blocking, the membranes were washed 3X 5 minutes with TBS-T and covered in a 
solution containing the primary antibody at the appropriate dilution in TBS-T with 2% BSA 
and incubated overnight at 4°C on a shaker. The membranes were then washed 6X 5 minutes 
each wash in TBS-T and incubated with appropriate dilutions of horseradish peroxidase-
linked secondary antibodies prepared in 5% milk or 2% blocking solution. 
The detection method used in all membrane developments was ECL Advance (GE 
RPN2135). The product was applied to the membranes as per manufacturer's instructions. 
Autoradiography films were placed against the membranes to detect the chemiluminescent 
signal emanating from bound secondary antibody. 
Developed films were scanned as images of TIFF format, without compression, for 
quantification of the bands. Using ImageJ software (v. 1.45s), the film images were opened, 
inverted and quantified using the software's "Gel" function. With this method, each selected 
lane is quantified (upon the command "Plot lanes") and the intensity of each lane is provided. 
The relative expression of the proteins of interest in each lane was calculated with the ratio of 
the intensity of the protein of interest over the expression of a housekeeping protein such as 
GAPDH. 
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II.9. Statistical Analysis 
All results are presented as the mean ± SEM. All data were processed using Prism 5 software 
(GraphPad Software, California, USA). One-way ANOVA with Tukey's post-test was 
performed when specified. Grouped data were analyzed using two-way ANOVA. When 
significance was obtained, groups were further compared using unpaired student t-test. 
Results were considered significant when p < 0.05.  
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III. RESULTS 
III.1. Standardization of Experimental Conditions 
III.1.1. H9c2 cells are a good model of cardiomyocyte in simulated 
ischemia-reperfusion experiments 
Commercially available H9c2 cells were examined for their applicability in the present study 
by immunofluorescent detection of cardiomyocyte and functional markers. As presented in  
Figure 5, all the cells expressed cardiac transcription factor GATA-4 (Fig. 5A) 
cardiomyocyte contractile protein troponin (Fig. 5B) as well as oxytocin receptor (OTR, Fig. 
5C) and vasopressin receptor type 1a (V1a, Fig. 5D). 
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Figure 5. H9c2 cells express cardiomyocyte proteins and receptors of the oxytocin 
system. 20X micrographs of immunofluorescent staining of H9c2 with A. Mouse anti-
GATA-4; B. Mouse anti-Troponin T; C. Goat anti-oxytocin receptor (OTR); D. Goat anti-
vasopressin type 1a receptor (V1a); E. Mouse IgG; F. Goat IgG. Arrows indicate specific 
staining of the receptors. Bars represent 10 µm.  
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III.1.2. Viability of H9c2 cells 
In order to routinely study the effects of oxytocin on cardiomyocyte survival, we required a 
reliable method to assess cellular viability. One such method is the colorimetric detection of 
formazan production, which is an indicator of cellular metabolic viability110.  
As presented in Figure 6, the assay provides a linear correlation between the number of H9c2 
cells seeded and the absorbance at 490 nm between 400 and 6400 cells per well of a 96-well 
plate (r2 = 0.9942 for the linear regression between 400 - 6400 cells/well). The optimal 
seeding density for accurate viability estimation was determined to be 3,200 cells per well of 
a 96-well plate, equivalent to 103 cells/cm2, as this provided a detectable signal ≥ 0.150 
absorbance units after 2 hours of reperfusion while maintaining < 80% confluence in all 
experimental wells. The production of formazan is no longer linearly related to seeding 
density at 12800 cells/well (40,000 cells/cm2). 
 
Figure 6. Formazan production is linearly related to H9c2 seeding density up to 20,000 
cells/cm2. Effect of H9c2 seeding density on tetrazolium salt reduction capability. Cells were 
seeded at the indicated densities in each well of a 96-well plate (0.32 cm2) and allowed to 
attach overnight. Cells were incubated for 2 hours with MTS tetrazolium salt and the 
absorbance at 490 nm was measured with a microplate reader. The absorbance of the blank 
(no cells) control was subtracted from all values. 
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III.1.3. Simulated ischemia-reperfusion (IR) protocol 
We sought a simulated ischemia-reperfusion protocol that produced a significant reduction in 
cell viability. Using the protocol presented in Figure 7, different lengths of incubation under 
hypoxic conditions were tested in the presence of DMEM 1% FBS or in an ischemic 
buffer111 that simulates the conditions of the ischemic myocardium.  
 
Figure 7. Experimental simulated ischemia-reperfusion (IR) protocol. Sub-confluent 
monolayers of H9c2 cells were covered in warm ischemic buffer and placed inside an anoxic 
chamber for 2 hours at 37°C. The cells were "reperfused" with pre-equilibrated warm 
DMEM containing 1% FBS under normal atmospheric oxygen conditions and further 
incubated for 2 - 4 hours.  
 
As presented in Figure 8A, two hours of hypoxia in the presence of DMEM with 1% FBS 
yielded a 5.6 ± 1.1% reduction in cell viability, whereas the same length of hypoxia in 
combination with the simulated ischemia buffer provided a 14.2 ± 2.6% reduction in cell 
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metabolic viability (Fig. 8B, p = 0.0131 vs. DMEM 1% FBS). In addition, viability in the 
simulated ischemia buffer, but not in DMEM, decreased steadily as a function of the time of 
exposure to hypoxia (Fig. 8). 
 
Figure 8. H9c2 viability after various times under hypoxic conditions. Cells were covered 
either in A. DMEM 1% FBS or in B. simulated ischemia (SI) buffer and placed inside a 
humidified hypoxic chamber (Billups-Rothenberg Modular Incubator Chamber) for 0.5, 1, 2 
and 4 hours. After the indicated times, the cells were removed from the hypoxic chamber and 
moved into normal incubation conditions, and the cells' medium or SI buffer was replaced 
with fresh DMEM containing 1% FBS. After a brief equilibration period (10-20 minutes), 
MTS was added to each experimental well. Plates were then incubated at 37°C for the 
remainder of 2 hours of reperfusion (1 hr 40 min to 1 hr 50 min). Results are presented 
normalized to normoxic control viability.  
 
III.1.4. siRNA-mediated knockdown of OTR 
III.1.4.1. Transfection efficiency determined using AF555-labelled negative 
control siRNA sequence 
The knock down of the expression of OTR was performed with 1, 5 and 10 nM of two 
different commercially-available siRNA sequences complementary to OTR mRNA. For a 
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control and to optimize the transfection conditions, we used equimolar doses of a negative 
control siRNA sequence (scrambled).  This reagent is labelled with a red fluorescent tag 
(Alexa Fluor 555) to enable the visualization of siRNA incorporation into the cells and has 
no silencing effect on any gene. Mock transfection, in which the siRNA sequences are 
provided in the absence of transfection reagent, were carried out in each optimization 
experiment as demonstrated in Figure 9. 
Incubation of scrambled siRNA with cells was performed during 24 (Fig. 9A) and 48 hours 
(Fig. 9B). Analysis of the ratios of incorporated siRNA fluorescence to DAPI fluorescence 
emitted from the cells' nuclei recorded by inverted microscope demonstrated that a final 
concentration of 5 nM siRNA provided the optimal transfection efficiency at both time points 
(Fig. 9A and B). Overall siRNA incorporation was higher at 24 hours post-transfection than 
at 48 hours (Fig. 9C). This led us to introduce a new time condition of 48 hours with a re-
transfection after 24 hours. In subsequent tests, this condition revealed optimal siRNA 
incorporation (Fig. 9D). The final protocol of siRNA experiments is presented in Figure 9E.  
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Figure 9. Optimization of siRNA-mediated knockdown of OTR. Effect of siRNA 
concentration on transfection efficiency at 24 and 48 hours post-transfection. The relative 
integrated density of the fluorescent siRNA sequence/DAPI fluorescence was used as 
measurement of the presence of siRNA within the cells after A. 24 and B. 48 hours with 
different concentrations of siRNA and 0.25% v/v transfection reagent used. C. Effect of the 
concentration of transfection reagent on transfection efficiency with different concentrations 
of siRNA. D. Effect of exposure time on siRNA (5 nM, 0.25 % v/v transfection reagent) 
incorporation within the cells. A double transfection with 5 nM  and an incubation of 48 hr 
provided the optimal siRNA incorporation.  
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III.1.4.2. Confirmation of OTR knockdown 
As demonstrated in Figure 10, immunofluorescent staining of transfected cells as well as 
Western blot were used to confirm the effective knockdown of OTR protein expression.  
Western blot analysis revealed a reduction in OTR expression of 65 ± 7% as compared to 
control siRNA-transfected cells (Fig. 10B). 
 
Figure 10. siRNA-mediated knockdown of OTR decreased OTR expression after a 
transfection with 5 nM siRNA every 24 hours for 48 hours using 0.25% v/v transfection 
reagent. A. Reduction of OTR-specific immunofluorescence by siRNA treatment. Staining 
of OTR (green) and DAPI (blue) B. Western-blot quantification of the control and OTR 
siRNA-treated H9c2 cells.  
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III.2. Oxytocin protects cardiomyocyte viability 
III.2.1. Pre-treating H9c2 cells with oxytocin protects them from death 
after simulated ischemia-reperfusion 
We74 and others70 had previously reported that OT preconditioning improves myocardial 
functional recovery in animal as well as in vitro models of cardiac ischemia - reperfusion. 
We thus investigated whether OT treatment in our experimental IR model could elicit 
protection of H9c2 cells against ischemia - reperfusion damage. 
Figure 11A presents the treatment schedule of OT in the IR protocol. OT (1 nM) was 
administered beginning 15 minutes prior the induction of ischemia and maintained 
throughout the IR experiment. As presented in Figure 11B, OT administered at a 
concentration of 1 nM at all points of our IR protocol protected H9c2 cell metabolic viability 
as measured by the MTS test, restoring viability to 97.4 ± 2.3 % of normoxic control, as 
compared to 88.4 ± 1.5% in untreated IR (p < 0.05 vs. OT-treated).  
To investigate whether the protection of viability induced by OT was attributable to 
decreased cell mortality, we evaluated cell death in IR with and without OT treatment. Using 
the TUNEL assay, we investigated whether OT treatment prevented cell death as evaluated 
by nuclear DNA fragmentation. In normal control conditions (normoxia), H9c2 cells 
displayed 1.69 ± 0.13 % TUNEL - positive nuclei (Fig. 11C). The cells exposed to IR 
displayed 2.74 ± 0.39 % of TUNEL - positive nuclei (p < 0.05 vs.  Normoxic group), and 
supplementation with 1 nM of OT resulted in a decrease in the proportion of TUNEL - 
positive nuclei to 1.39 ± 0.19 % (p = 0.0048 vs. IR; p = 0.2084 vs. normoxia, Fig. 11C). 
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In order to verify the validity of our results obtained with H9c2 cells, we repeated the 
experiment using isolated adult rat ventricular cardiomyocytes (ARVCMs). As presented in 
Figure 11D, ARVCMs in culture displayed relatively higher numbers of dead cells as 
compared to H9c2 cells under basal (normoxic) conditions (18.2 ± 7.2 TUNEL-positive 
nuclei in ARVCMs normoxic control vs. 1.69 ± 0.13 % in H9c2 normoxic control). In 
ARVCMs exposed to IR, a 2-fold increase in cell death was noted, to 36.3 ± 11.2 % of cells. 
In response to treatment with 1 nM OT, the number of cells displaying dead nuclei decreased 
significantly vs. untreated IR control (p < 0.05) to 3.4± 2.3 %, and the results were 
statistically different from normoxic control (Fig. 11D). 
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Figure 11. Preconditioning cardiomyocytes with 1 nM OT beginning 15 minutes prior 
to the onset of ischemia and maintained throughout the simulated ischemia-reperfusion 
(IR) experiment prevents cell death.  A. IR protocol showing the times of OT addition as 
well as the controls. B. Viability after 2 hours of simulated ischemia and 2 hours of 
reperfusion, with and without OT treatment. Values reported as fold change with respect to 
normoxic control cells. *** p < 0.001 vs. normoxic control, & p < 0.05 vs. untreated IR. C. 
TUNEL assay of H9c2 cells and D. isolated adult rat ventricular cardiomyocytes (ARVCMs) 
following IR. ** p < 0.01 vs. normoxia; & p < 0.05 vs. untreated IR.  
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III.2.2. Oxytocin protects cell viability optimally if administered at the 
onset of reperfusion  
In the preceding experiment, OT was administered throughout the simulated ischemia-
reperfusion experiment, beginning at 15 minutes prior to the onset of ischemia, during 
ischemia and in the reperfusion medium. To investigate the specific point of OT action 
during IR, we added OT at three different points of the IR experiment. 1) In the OT pre-
conditioning group, we added 1 nM of OT to H9c2 culture 15 minutes prior to the onset of 
ischemia (OT pre-con); 2) in OT-ischemia group, we added OT during the 2-hour ischemic 
period (OT ischemia); 3) in the OT postconditioning group, OT was added only at the onset 
of reperfusion, dissolved in reperfusion media (OT post-con). In group 4, OT was present 
during all three time points of the IR experiment (OT-all). As shown in Figure 12A, 
compared to untreated IR control (column 1), OT treatment before ischemia only (pre-con) 
had no effect on cell metabolic viability measured by formazan production (Fig. 12A, 
column 2); OT presence during ischemia increased cell viability by 9.7 ± 2.5% (p < 0.05, 
Fig. 12A, column 3); OT presence after ischemia (at post-con) increased cell viability by 
15.8 ± 3.5% (p < 0.001, Fig. 12A, column 4), while OT-all increased viability by only 
7.1±1.8% (p < 0.01, Fig. 12A, column 5) compared to untreated IR.  
Investigations of whether preconditioning of H9c2 cells with OT could increase the 
protection against IR with different combinations of OT administration brought negative 
results (Fig. 12B). Following the observation that protection was maximal if OT was 
supplied at reperfusion (post-con), different combinations of OT administrations during the 
pre-con and ischemic phases in combination with post-con were investigated (Figure 12). As 
shown in Figure 12C, the cells treated with OT during reperfusion only displayed optimal 
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viability (15.8 ± 3.6% higher than untreated control, p < 0.001). OT administration at the 
ischemic and reperfusion periods as well as at all phases (OT-all) significantly improved 
viability (Fig. 12C columns 3 and 5, up by 11.5 ± 3.5% and 7.1 ± 1.8%, p < 0.05 vs. 
untreated control). OT administered only at reperfusion provided significantly better 
protection than when done so in combination with an OT treatment prior to ischemia (Fig. 
12C column 2 vs. 4 and 5).   
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Figure 12. OT protects cardiomyocyte viability optimally if administered exclusively at 
reperfusion. A. A single dose of OT was administered either before ischemia (Pre-con, col. 2), 
during ischemia (Ischemia, col. 3), at reperfusion (post-con, col. 4) or at all three times (col.5). OT 
ischemia, post-con and OT-all treatments provided significant protection of viability, with OT post-
con providing the strongest protection. B. OT pre-con with combinations of OT treatment during 
ischemia and reperfusion. OT-all (col. 5) is the only condition in which OT treatment before ischemia 
resulted in a significant improvement in viability after IR. C. OT Postconditioning with combinations 
of OT treatment prior to and during ischemia. OT administered only at reperfusion provided the 
strongest protection, however, OT present during ischemia as well as in reperfusion (column 3) also 
significantly improved viability. The numbers indicate the corresponding visual representation of the 
protocol followed for that column * p < 0.05, ** p < 0.01, *** p < 0.001 vs. untreated control; 
& p < 0.05, && p < 0.01, &&& p < 0.001.  
61 
 
 
III.2.2.1. OT administered at reperfusion protects optimally at concentrations 
ranging from 1 - 250 nM 
Figure 13 presents the concentration-response analysis of OT administered at the post-con 
period. The results revealed significant protection starting at a concentration of 1 nM of OT, 
with an optimal protection at 62.5-125 nM (up by 55% compared to untreated IR, to 89.5 ± 
3.2% of normoxic control, p < 0.001).  Importantly, lowered OT protection was noted when 
OT concentration exceeded 500 nM.   
 
Figure 13. Concentration -response of oxytocin administered at reperfusion. A. Initial 
experiments revealed an optimal protection around a concentration of 1 nM OT. B. Serial 
dilution analysis using concentrations reported112 to stimulate a known cardioprotective 
pathway (Pi3K-Akt)  *** p < 0.001, ** p < 0.01, * p < 0.05 vs. Untreated IR; 
&&& p < 0.001 vs. normoxia.  
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III.3. The protection afforded by OT is mediated by oxytocin 
receptor 
III.3.1. OTA concentration-dependently blocks the protective effect of OT 
Oxytocin can trigger intracellular signaling via its interaction with oxytocin receptors (OTR) 
as well as through vasopressin receptors. To evaluate whether OTR-specific signaling was 
involved in the protection we observed upon OT treatment, experiments using an antagonist 
specific against OTR (OTA). As shown in Figure 14, the protective effect of 1 nM OT during 
the postconditioning period was abolished by the administration of OTA at concentrations of 
0.1, 1 and 10 nM.  
 
Figure 14. OT antagonist OTA concentration-dependently abolishes the protective 
effect of OT treatment at reperfusion. && p <0.01, &&& p < 0.001 vs. IR + OT 1 nM at 
reperfusion; ** p < 0.01.   
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III.3.2. OTR knockdown reverses the protective pattern observed by OT 
treatment on cell death 
Figure 15 presents the results obtained from siRNA knockout experiments designed to 
evaluate the role of OTR in cell protection against IR. The standardization of the experiment 
has been presented in section III.1.4.1 (Figure 10). 
H9c2 cells were transfected with siRNA sequences targeting OTR (siOTR, Fig. 15B) or with 
control scrambled siRNA (scr, Fig. 15A). After 48 h, the cells were exposed to IR and cell 
death was evaluated by DNA fragmentation detected by the TUNEL method. Under 
normoxia, scr cells (1.3 ± 0.7%) and siOTR cells (1.6 ± 0.6%) displayed a similar proportion 
of dead nuclei (Fig. 15A and B). In scr cells subjected to IR, the proportion of dead nuclei 
increased to 11.7 ± 4.5%; this increase was prevented by treatment with 1 nM of OT to 3.8 ± 
0.8% (p = 0.0027, Fig. 15A). Upon IR conditions, siOTR-cells displayed an increase in cell 
death compared to normoxic control to 5.9 ± 1.9 %. Interestingly, OT treatment of siOTR 
cells increased cell death almost 3-fold to 16.7 ± 2.9 % (p< 0.05, Fig. 15B).   
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Figure 15. OTR signaling is necessary for OT-induced protection of viability. A. Control 
(scrambled) siRNA-transfected cells display a significant protection by OT. * p < 0.05, 
** p < 0.01. B. siRNA-mediated OTR knockdown reverses the protective pattern observed 
by OT treatment on cell death. The siRNA transfection and experimental schedule of OT 
treatment is presented at the top panel  ** p < 0.01 vs. IR untreated.   
 
III.3.3. A high concentration of vasopressin, administered at reperfusion, 
exerts a mild protection of metabolic viability in H9c2 cells 
Given the unexpected results obtained with OTR knockdown experiments, we hypothesized 
that in conditions of OTR down-regulation, OT may elicit a deleterious effect via vasopressin 
receptor 1a, which is expressed in H2c9 cells (See  
Figure 5). The effect of vasopressin (AVP) administration (0.1 - 1000 nM) during the 
reperfusion phase of the IR protocol is presented in Figure 16A. Data analysis indicates that 
AVP administered at reperfusion exerts no effects at concentrations of 0.1 – 100 nM,  but 
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provides a significant cell protection at the highest concentration of AVP tested (1000 nM, to 
84.0 ± 2.1 % of normoxic control vs. 76.8 ± 1.2 in AVP-untreated IR control, p < 0.05).  
 
III.3.4. An antagonist to vasopressin receptors V1a and V2 protects 
viability only in the absence of oxytocin 
For the study of the effects of AVP receptor blockade, Conivaptan, an antagonist of 
vasopressin receptors V1a and V2 has been employed. Figure 16B demonstrates that 
Conivaptan administration (50 nM) alone increased cell viability (to 77.9 ± 3.7% compared 
to 57.8 ± 2.7% in vehicle-treated control, p = 0.0009). Two-way ANOVA analysis revealed 
that the concentration of OT significantly influences cell protection (p = 0.0449) while the 
presence of Conivaptan tended to influence cell protection (p = 0.0615). Two-way ANOVA 
demonstrated a significant interaction between OT concentration and Conivaptan on cell 
viability using the MTS assay (p = 0.0121, Fig. 16B) 
Detailed analysis by student t test demonstrated that the cells treated with vehicle (DMSO) 
and with OT at doses of 125, 250, 1000 (p < 0.05) and 500 nM ( p < 0.01) displayed a 
significant improvement in viability. In the presence of Conivaptan, the protective effect of 
OT was reduced. The level of cell protection in samples treated by OT + Conivaptan was at 
the range observed in Conivaptan control (Fig. 16B).  
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Figure 16. The role of vasopressin system in OT-mediated protection. A. Vasopressin 
administered at reperfusion protected cell viability only in the highest concentration tested 
(1000 nM). *** p < 0.001 vs. untreated IR.  B. Vasopressin receptor V1a and V2 antagonist 
Conivaptan (50nM) protects cell viability in the absence of OT. There is a significant 
interaction (p =0.0121) of OT and Conivaptan actions as estimated by two-way ANOVA. 
Experimental protocol of Conivaptan treatment in IR is presented at the top of the figure.  
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III.4. Mechanisms of oxytocin-induced cytoprotection 
III.4.1. Oxytocin decreases the formation of reactive oxygen species (ROS) 
in cardiomyocytes exposed to IR  
We hypothesized that modulation of oxidative stress may be one of the mechanisms of OT-
induced protection. The determination of intracellular oxidative formation was based on the 
oxidation of 2 μM of 5-(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate, 
acetyl ester (CM-H2DCFDA, Invitrogen). The acetate group in this cell-permeable probe is 
cleaved by intracellular esterases; subsequent oxidation releases fluorescent 2',7'-
dichlorofluorescein that is retained within the cell, thus facilitating long-term studies on 
intracellular oxidative potential.  
As shown in Figure 17A, intracellular ROS increased in ARVCMs upon simulated ischemia-
reperfusion and was normalized by treatment with 1 nM OT beginning at 15 minutes prior to 
ischemia and maintained throughout the experiment (Fig. 17A).  
To verify the hypothesis that OT exerts protection against ROS at reperfusion, H9c2 cells 
were treated with different concentrations of OT exclusively during the reperfusion period. 
As demonstrated in Figure 17B, the production of ROS was significantly attenuated at 
concentrations of 62.5-1000 nM of OT but not at a concentration of 1 nM after 2 hours of 
reperfusion.   
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Figure 17. OT treatment prevents ROS formation following simulated ischemia-
reperfusion. A. Intracellular ROS production in ARVCMs. Cells were incubated with the 
CM-H2DCFDA probe in warm KRH buffer at 37°C for 30 minutes prior to IR protocol. Cells 
were then washed, and 1 nM of OT was added to the cells prior to the induction of ischemia, 
and maintained throughout the experimental time points. Fluorescence was measured after 1 
hour of reperfusion. *** p < 0.001 B. Intracellular ROS production in H9c2 cells after 2 
hours of reperfusion with OT treatment at the onset of reperfusion. After 1 hour of 
reperfusion in the presence of OT, cells were incubated with the CM-H2DCFDA probe in 
warm KRH buffer at 37°C for 30 minutes. Cells were then washed and incubated in normal 
conditions for an additional 30 minutes (2 hours total reperfusion time). Fluorescence was 
measured using a microplate reader set at excitation 485/20 nm, emission 528/20 nm. 
* p < 0.05, ** p < 0.01 vs. control.  
 
III.4.2. OT treatment in normoxic conditions causes an increase in 
intracellular ROS production 
Interestingly, these experiments revealed that under normoxic conditions, OT treatment alone 
is sufficient to trigger a short-lived burst in intracellular ROS. H9c2 cells were incubated 
with the CM-H2DCFDA probe, which becomes fluorescent upon oxidation by intracellular 
ROS and is retained within the cells. Figure 18A shows the effect of OT on ROS generation 
69 
 
 
after 5 minutes: a concentration of 1 nM OT increased intracellular ROS by 27.7 ± 6.1 % 
(p < 0.001 vs. control); 62.5 nM OT induced a 23.5 ± 6.2 % (p < 0.01 vs. control); 125 nM 
OT induced a 21.3 ± 3.9 % increase in ROS (p < 0.01 vs. control), whereas 1000 nM OT 
induced a 13.4 ± 4.1 % increase in intracellular ROS (n.s., Figure 18A). A similar pattern 
was observed after 15 minutes (Figure 18B), where OT increased ROS maximally at a 
concentration of 1 nM (up by 25.4 ± 5.7 % , p < 0.01 vs. control); but also significantly 
increased intracellular ROS by 23.6 ± 6.2 %, p < 0.01) with 62.5 nM OT, by 24.2 ± 4.7% 
with 125 nM OT (p < 0.01 vs. control) and by 18.5 ± 4.8 % with 1000 nM OT (p < 0.05 vs. 
control). As Figure 18C demonstrates, after 30 minutes of OT treatment only a concentration 
of 1000 nM was sufficient to induce a significant ROS production (up by 15.3 ± 4.5 %, 
p < 0.05 vs. control). At the early time points of 5 and 15 minutes, intracellular ROS 
production was optimally exerted in lower OT concentrations of 1 - 62.5 nM and less 
effective or absent when OT was added at 125-1000 nM; however, this pattern was not 
maintained after 30 minutes of treatment with OT (Fig. 18C). Thus, OT triggers a short-lived 
burst in ROS production. This phenomenon may be involved in OT signaling. 
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Figure 18. Intracellular ROS production after stimulation of H9c2 cells with OT.  A. 5 
minutes; B. 15 minutes, and C. 30 minutes of treatment with OT, under normoxic conditions. 
The treatment performed at different OT concentrations was  assessed by fluorescence 
emitted by the oxidized probe CM-H2DCFDA * p < 0.05, ** p < 0.01, *** p < 0.001 vs. 
control.  
 
III.4.3. OT preconditioning of H9c2 cells protects them from doxorubicin-
induced cytotoxicity 
The stimulation of ROS by OT-preconditioned H9c2 cells led us to the hypothesis that 
reactive oxygen species released from the mitochondria during a brief OT treatment, induce 
preconditioning of cardiomyocytes and cell resistance to ischemia - reperfusion injury. To 
test this hypothesis we treated H9c2 cells with OT prior to exposure to Doxorubicin (Dox). 
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Dox is a drug commonly used for anti-cancer therapy but whose use is limited due to its 
cardiotoxicity targeting  mitochondria113. Figure 19 demonstrates that a 24-hour Dox 
treatment (1 µM) induced a reduction in cell viability to 72.9 ± 3.7% of Dox-untreated 
control, p < 0.0001. Of the tested concentrations, 1000 nM OT had the maximal effect in 
protection of cells and increased viability to 86.7 ± 4.1 % of Dox-untreated control. Two-way 
ANOVA reveals a significant effect of OT treatment (p < 0.0001) and of Dox treatment 
(p < 0.0001) but an insignificant interaction (p = 0.9744). 
In the absence of Dox, OT treatment for 24 hours (62.5 and 1000 nM) also increased 
metabolic viability (up by 13.2 ± 2.6%, p < 0.001 and 14.3 ± 2.7 % p < 0.001 respectively vs. 
untreated control).  
 
Figure 19. OT partially protects from doxorubicin - induced H9c2 cell death.  Cells were 
pre-treated with varying doses of OT for 30 minutes prior to the addition of 1µM Dox for 24 
hours (OT was not removed from  the media prior to the addition of Dox). OT treatment for 
24 hours induced a significant increase in viability both in the presence and absence of Dox. 
Two-way ANOVA reveals a significant effect of OT treatment (p < 0.0001), of Dox 
treatment (p < 0.0001) but insignificant interaction (p = 0.9744). *** p< 0.001 vs. Untreated 
vehicle; &&& p < 0.001 vs. Dox-treated, OT-untreated.  
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III.4.4. Pi3K-Akt-eNOS signaling is involved in OT-mediated protection 
from simulated ischemia - reperfusion 
III.4.4.1. Pi3K inhibitor Wortmannin blocks the protective effect of oxytocin 
Previous studies demonstrated that OT stimulates phosphatidylinositol-3-kinase (Pi3K)/Akt 
pathway in cardiomyocytes76 and mesenchymal cells114. Activation of this pathway has been 
shown to be essential for the anti-apoptotic effects of H2O2-stimulated preconditioning of 
cardiomyocytes 115. In addition, the maintenance of the activated form of Akt has been found 
to be protective against Dox-induced cardiomyopathy116. 
Experiments with Wortmannin (Wort), an irreversible covalent inhibitor of Pi3K, 
demonstrated that this pathway is necessary for OT-induced protection of metabolic viability 
as measured by formazan production in IR experiment using H9c2 cells (Fig. 20). ANOVA 
analysis demonstrated significant effect of interaction of OT and Wort treatments 
(p = 0.0068), OT effect (p < 0.001) and Wort dose effects (p < 0.001). Detailed analysis 
demonstrated that Wort at the concentration of 1-1000 nM did not influence metabolic 
viability of H9c2 cells in the absence of OT, which indicates lack of toxic effects of this 
compound on the cells at the concentrations used. As shown in Figure 20, OT treatment 
induced a 25.5 ± 4.4% increase in metabolic viability of H9c2 cells compared to untreated 
control; this protection decreased to 15.1 ± 1.5% in the presence of 10 nM Wort. 
Concentrations of 100 and 1000 nM Wort completely blocked the OT-induced protection of 
cells. 
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Figure 20. The phosphatidylinositol-3-OH kinase (Pi3K)-Akt pathway inhibitor, 
Wortmannin (Wort) blocked OT-mediated cell protection in IR conditions in a 
concentration - dependent manner. H9c2 cells were exposed to the indicated 
concentrations of Wortmannin in the ischemic buffer and again in the reperfusion medium, 
with or without OT. N=6  in each group/  Symbols: # p < 0.05, ## p < 0.01 effect of  OT 
treatment;  * p < 0.05  effect of OT treatment in presence of  1-1000 nM Wort vs.  the OT in 
control.  
  
III.4.4.2. OT stimulation causes Akt phosphorylation (Thr308) and co-localization with 
mitochondria in the perinuclear region  
The protection from IR mediated by OT was blocked by the Pi3K-Akt pathway inhibitor 
Wortmannin in a concentration - dependent manner; therefore, we hypothesized that 
protection afforded by OT in IR experiment is related to Akt phosphorylation. Because there 
are reports suggesting that p-Akt translocation inside the cell structures is associated with 
enhanced cardiomyocyte viability29,38 we performed immunofluorescence studies of p-Akt in 
cells stimulated with OT. Using inverted immunofluorescence microscopy, we noted that in 
normoxic conditions, cells treated for 30 min with 62.5 nM of OT, displayed increase of p-
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Akt (Thr308) staining and specifically, p-Akt accumulated in intracellular structures 
apparently inside, or around, the cell nuclei (Fig. 21). We hypothesized that in some cells 
stimulated with OT, p-Akt will co-localize with mitochondria. Indeed, as presented in Figure 
21, the co-staining with mitochondrial marker Cox IV showed partial co-localization of this 
protein with p-Akt (detected as yellow-orange staining in the merged photo) in the cytoplasm 
of OT-treated cells. 
More details of the co-staining of p-Akt and Cox IV are presented at higher magnifications 
(Fig. 22) and by confocal microscopy (Fig. 23 and 24). Figures 22 and 23 present 
accumulated p-Akt apparently within the nuclei of OT - treated cells (white arrows). Detailed 
observation of these cells indicated that Cox IV protein, which was not seen in the nuclei of 
control cells, was transmitted to the nuclei of OT-stimulated cells where it co-localizes with 
p-Akt (Fig. 22-24). As marked by the arrows in Fig. 22, Cox IV staining was visible in the 
nuclear region, corresponding to the localization of p-Akt. In some micrographs, the structure 
composed of p-Akt and Cox IV appears associated with the nuclear envelope but not present 
inside the nuclei (yellow arrows in Fig. 23, 24), whereas in others (white arrows Fig. 22-24) 
p-Akt and Cox IV accumulated and co-localized in well-defined structures mostly in what 
appears to be the inside of the cells' nuclei in OT-treated cells. 
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Figure 21. OT treatment causes Akt phosphorylation and accumulation in and around the 
nuclei of H9c2 cells. 10X magnification micrographs of H9c2 cells following 30 min of 
treatment with OT 62.5 nM. Cells were fixed and probed using antibodies against phosphorylated 
Akt (Thr308, green) and mitochondrial cytochrome c oxidase/respiratory complex IV present on 
the mitochondrial inner membrane (COX IV, red).  Following OT treatment, p-Akt appears 
accumulated in a distinct structure inside (white arrows) and/or around (yellow arrows) the cells' 
nuclei. 
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Figure 22. OT treatment causes p-Akt phosphorylation in a structure within the nuclei. 
Inverted microscope micrographs of H9c2 cells following 30 min of OT treatment and 
probed with p-Akt (T308, green) and mitochondrial complex IV (Cox IV, red).  
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Figure 23. OT treatment causes p-Akt phosphorylation in a structure within the nuclei. 
Micrographs of H9c2 cells following 30 min of OT treatment and probed with p-Akt (T308. 
green) and mitochondrial complex IV (Cox IV, red). using A. Inverted microscope and B. 
Optical slices demonstrating precise c-localization of p-Akt (T308) and Cox IV apparently 
concentrated in a structure within and around the nuclei of H9c2 cells treated with OT (62.5 
nM) in normoxic conditions.  
B 
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Figure 24. OT treatment causes p-Akt phosphorylation in a structure around the nuclei. 
Optical slices demonstrating precise co-localization of p-Akt (T308, green) and Cox IV (red) 
apparently concentrated in a structure around the nuclei of H9c2 cells following 30 min of 
OT treatment in normoxic conditions.  
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In conclusion, the confocal analysis presented in Figures 23 and 24 revealed that p-Akt co-
localizes precisely with mitochondrial cytochrome C oxidase (Cox IV) in the perinuclear cell 
region. Although this phenomenon was also visible in some cells treated with different doses 
of OT (1, 500 and 1000 nM, results not shown), the effect was strongest at a dose of OT 
62.5 nM. The observed structure is present most clearly in normoxic cells after 30 minutes of 
OT treatment (Fig. 21-24). However, it was also observed following the IR protocol, after 30 
minutes of OT treatment during reperfusion (Fig. 25).  
 
Figure 25. H9c2 cells subjected to hypoxia and treated with OT at reperfusion period 
display Akt phosphorylation and p-Akt and Cox IV translocation in the perinuclear 
region.  Optical slices of untreated and after 30 min of OT (62.5 nM) treatment following 
simulated ischemia - reperfusion.  
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III.4.4.3. OT treatment causes eNOS phosphorylation (Ser1177) and nuclear co- 
localization with p-Akt (Thr308) 
Given the evidence obtained that cGMP production via soluble GC was an essential part of 
OT-induced protection of cell viability, we performed investigations of endothelial nitric 
oxide (eNOS) phosphorylation status following different lengths of OT treatment under 
normoxic conditions.  
Figure 26 presents confocal micrographs demonstrating the time course of eNOS 
phosphorylation (Ser1177, red) and nuclear accumulation after 0, 5, 15 and 30 minutes of 
treatment with OT 62.5 nM. Interestingly, closer analysis of nuclear p-eNOS revealed a 
distinct structure of p-eNOS (Ser1177) and p-Akt (Thr308) proteins co-localizing within the 
nuclei of H9c2 cells (Figure 27); this intra-nuclear structure appears very similar to the one 
observed previously (Figure 23, bottom panel). 
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Figure 26. OT causes p-eNOS accumulation in the nuclei of H9c2 cells. Time-course of 
changes in the abundance and intracellular localization of phoshorylated forms of eNOS 
(Ser1177, red) and Akt (Thr308, green) during 30 min of OT treatment. Nuclei are stained 
with DAPI in blue.  With time, the co-localized areas are stained mostly in cell nuclei and 
appear in orange color.   
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Figure 27. Co-localization of phosphorylated eNOS (p-eNOS, red) and phosphorylated 
Akt (p-Akt, green) in H9c2 cells stimulated with 62.5 nM of OT.  Optical slice of H9c2 
cell nucleus after 30 minutes of treatment with OT, and demonstrates the appearance of 
phosphorylated eNOS (Ser1177, red) and phosphorylated Akt (Thr308, green) structures in 
the nuclei of cells treated for 30 min with 62.5 nM of OT.  
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III.4.5. The cGMP/PKG pathway mediates OT-induced cardioprotection 
III.4.5.1. cGMP-dependent protein kinase (PKG) activity 
Previous experiments in vivo demonstrated that nitric oxide (NO) plays a role in OT-
stimulated cardiac protection 71,74 and acts against cardiac ischemia-reperfusion injury in 
association with PI3K/Akt activation71. NO signaling is known to stimulate the activity of 
soluble guanylate cyclase (sGC), which results in an increase in cyclic GMP (cGMP) 
production and increased activity of the pro-survival cGMP - dependent protein kinase 
(PKG).  To investigate the role played by PKG in OT-mediated cell protection against IR, 
H9c2 cells were treated with the PKG inhibitor KT-5823 (Figure 28) throughout the IR 
experiment, with or without 62.5 nM OT added at reperfusion. Figure 28 reveals that a 
concentration of 2 µM KT5823 blocks the protection induced by treatment with OT (p = 
0.0001 vs. OT Vehicle). Two-way ANOVA revealed a significant interaction (p = 0.0128) of 
OT treatment (p < 0.0001) and KT5823 concentration (p < 0.0001). 
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Figure 28. cGMP-dependent protein kinase (PKG) inhibitor KT-5823 blocks the 
protective effect of OT (62.5 nM) treatment at reperfusion. H9c2 cells were treated with 
the indicated concentrations of KT5823 throughout the duration of the IR experiment. A 
single administration of OT (62.5 nM) was done at the onset of reperfusion. Viability was 
determined after 4 hours of reperfusion. Significant interaction (p = 0.0128), OT treatment 
(p < 0.0001) and KT5823 concentration (p < 0.0001). ** p < 0.01; # p < 0.05, ## p < 0.001 
vs. SIR + OT vehicle.  
 
III.4.5.2. Guanylate cyclase activity  
In cells, cGMP is the activating substrate for PKG, and is produced by two major classes of 
guanylate cyclases: soluble (sGC) and particulate (pGC). The activation of sGC is associated 
predominantly with NO, whereas pGC is activated by natriuretic peptides. In order to further 
explore the OT cytoprotective mechanism associated with NO activation, we investigated the 
role of sGC activity in cells subjected to SIR. Figure 29 shows that sGC inhibitor ODQ has a 
significant effect on OT-induced viability protection, with two-way ANOVA revealed 
significant interaction (p = 0.009), OT treatment (p = 0.0412), and ODQ treatment (p < 
0.0001). OT treatment in the absence of ODQ induced a 19.0 ± 3.6 % increase in metabolic 
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viability (student t test p < 0.001 vs. untreated control, whereas the specific inhibition of sGC 
by the administration of 2µM ODQ blocked OT's protection of metabolic viability to 91.8 ± 
3.5 % of untreated control (p = 0.0004 vs. OT-treated, ODQ-untreated).  
Figure 29B demonstrates that a concentration of 0.2 µM of pGC inhibitor/natriuretic peptide 
antagonist A71915 prevents OT - induced protection of viability following IR. Two-way 
ANOVA reveals a significant interaction of OT and A71915 treatments (p = 0.0455). Student 
t test reveals that a treatment with 0.2 µM A71915 blocks OT's protective effect. OT alone 
increased viability (by 16.2 ± 5.0%, p < 0.001 vs. untreated control), whereas A71915 co-
administered with OT had a tendency to decrease viability to 98.9 ± 2.6 % of untreated 
control (p = 0.0574 vs. OT alone). These results suggest that OT exerts its cardioprotective 
effect via the generation of cGMP.  
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Figure 29. Inhibition of cGMP production blocks the protection induced by OT 
treatment at reperfusion. A. Soluble guanylate cyclase (sGC) inhibitor ODQ blocks the 
protective effect of OT at a concentration of 2 µM. &&& p < 0.001; *** p < 0.001 vs. OT-
treated, ODQ untreated control. B. Particulate GC antagonist A71915 partially blocks the 
protective effect of OT at a concentration of 0.2 µM. && p < 0.01.  
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IV. DISCUSSION 
Work from recent years has demonstrated that OT has the capacity to attenuate the 
myocardial damage resulting from myocardial ischemia -reperfusion injury. A variety of 
research groups around the world have reported impressive reductions in infarct size when 
the ischemic event was preceded by an administration of OT70,74,77,80–82. More interestingly 
from a clinical perspective, important reductions in infarct size are also observed when OT is 
administered at the onset of reperfusion71, or just prior to it83. However, the molecular 
mechanism indicating how oxytocin protects the cardiac cells in from ischemia – reperfusion 
injury is far from being explained. 
The results of this project demonstrate that oxytocin directly acts on cardiomyocytes to 
improve their survival during the acute phase of simulated ischemia - reperfusion. On the 
H9c2 cell line (a cardiomyocyte model) we revealed the pleiotropic mechanisms by which 
OT protection is induced. Using formazan production for the measurement of cell viability 
and metabolic activity, a significant cellular protection was observed at a concentration of 
1 nM of OT, with an optimal protection at 62.5-125 nM. A specific OT antagonist 
concentration-dependently blocked the protective effect of OT. Using the TUNEL 
methodology, it has been shown that OT treatment of H9c2 cells transfected with OT 
receptor siRNA increased cell apoptosis 3-fold in comparison to the control. The OT-induced 
increase in cell mortality in OTR siRNA cells could be mediated by vasopressin receptors. 
Indeed, blockade of AVP receptors by Conivaptan increased cell viability in IR conditions. 
OT treatment decreased the fluorescence of CM-H2DCFDA products in IR-treated cells 
indicating a decrease of intracellular reactive oxidative species (ROS). Interestingly, these 
experiments revealed that under normoxic conditions, OT treatment alone is sufficient to 
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trigger a short-lived burst in intracellular ROS. The OT protection of IR was blocked by the 
PI3K-Akt inhibitor Wortmannin. Correspondingly, using confocal microscopy, we noted that 
cells treated with OT displayed increased Akt (Thr308) phosphorylation and specifically, Akt 
was accumulated in ring-like structures associated with mitochondria and nuclei. The 
demonstration that KT-5823, inhibitor of protein kinase G (PKG) and ODQ, inhibitor of 
soluble guanylyl cyclase, reduced OT-mediated protection in IR, indicated the role of cGMP-
dependent protein kinase (PKG). Consequently, confocal microscopy demonstrated the 
increase of eNOS phosphorylation and its nuclear accumulation in cells treated with OT. OT 
protection in IR was also inhibited by ANP receptor antagonist, A71915.  
These data suggest that OT provides protection to the injured heart by pleiotropic 
mechanisms which include inhibition of ROS, inhibition of cardiomyocyte death and 
stimulation of cell protective Pi3K-Akt-PKG signaling and molecular trafficking. 
 
IV.1. Experimental Models 
IV.1.1. H9c2 cells are a good in vitro model of oxytocin signaling in 
cardiomyocyte ischemia - reperfusion 
The use of in vitro models of ischemia - reperfusion injury is necessary in order to study 
mechanistic details of cell death and signaling. The cell line H9c2 is an accepted model of 
cardiomyocyte amenable to manipulations. Our data demonstrates that H9c2 cells express 
both OTR and AVP receptor 1a along with cardiomyocyte - specific markers GATA - 4 and 
troponin T. In addition, select experiments were performed in parallel in primary cultures of 
adult rat ventricular cardiomyocytes as well as in H9c2 cells, and the results demonstrate that 
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in our experimental model H9c2 cells behave in a way comparable to adult cardiomyocytes 
in culture. 
As stated previously, ionic homeostasis and pH modulation are essential features of ischemia 
- reperfusion injury8. In our experiments, the use of an ischemic buffer proved indispensable 
for the consistent reduction of cell viability as a function of time of exposure of H9c2 cells to 
hypoxic conditions.  
The use of two different sequences of small interfering RNA (siRNA) targeting OTR allowed 
us to decrease the amount of OTR protein expressed by H9c2 cells while minimizing off-
target effects of each sequence. A scrambled siRNA control served to verify the experimental 
conditions, and in all cases tested the scrambled siRNA - treated cells responded in the same 
way as un-transfected cells, confirming that transfection with siRNA in itself was not enough 
to affect the phenotype of the cells.  
 
IV.2. OT protects cardiomyocyte survival 
IV.2.1. OT preconditioning directly protects cardiomyocyte survival 
Cardioprotective treatments aim to salvage cardiac function by protecting the survival of 
contractile cardiac cells, the cardiomyocytes, from death following ischemia - reperfusion 
injury. While the majority of the volume of the myocardium is composed of cardiomyocytes, 
there are many different cell types present such as fibroblasts and endothelial cells, and 
cardioprotective stimuli likely confer effects in all the cell types of the myocardium8. Cell-
cell interactions and paracrine signaling across cell types could confer the protected 
phenotype to cardiomyocytes without directly stimulating receptors on the cardiomyocytes 
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themselves. The presence of OTR on endothelial cells is well known, and oxytocin treatment 
stimulate angiogenesis117. To study whether oxytocin can directly trigger pro-survival 
signaling in cardiomyocytes, isolated primary cultures of rat cardiomyocytes as well as the 
cell line H9c2, derived from embryonic rat heart, were used in this study. With the use of an 
in vitro simulated ischemia - reperfusion protocol we were able to clearly demonstrate that 
treatment with OT beginning 15 minutes prior to the induction of ischemia and maintained 
throughout the experimental protocol can exert a protective effect on cardiomyocytes' 
metabolic viability and decrease the number of dead nuclei detected by TUNEL. Importantly, 
primary cultures of adult rat cardiomyocytes responded in the same pattern as H9c2 cells; 
confirming the validity of H9c2 cells as a model of adult cardiomyocyte. However, the 
relative proportion of dead cells was higher in primary cultures of adult cardiomyocytes 
compared to H9c2 cells.  
 
IV.2.2. OT exerts an optimal protective effect if administered only at 
reperfusion 
Our investigations into the specific point of OT action in the protection from ischemia - 
reperfusion revealed that OT protects optimally if administered at reperfusion. This 
observation is consistent with recent reports in the literature indicating a significant reduction 
in infarct size when OT is administered at the onset of reperfusion71,83. This agrees with the 
fact that the induction of cell death from ischemia - reperfusion injury is believed to take 
place in the first minutes of reperfusion8, and that ischemic preconditioning is known to 
confer resistance to cell death from ischemia - reperfusion by activating pro - survival 
kinases at reperfusion15. Thus, when a single OT administration was performed, protection 
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improved the closer OT was administered to reperfusion; with OT administration during 
ischemia only providing a small measure of protection. This is probably due to the fact that 
the first few minutes of reperfusion are critical in determining cell fate. Protective signaling 
triggered by an OT treatment during ischemia might still play a role in early reperfusion.  
Additionally, OTR signaling is known to become desensitized after prolonged OT 
stimulation56. Thus, in the case of multiple OT administrations (Fig. 12B and C), when OT is 
added prior to reperfusion as well as at the onset of reperfusion, OT signaling and thus kinase 
activation would be attenuated during the critical phase of reperfusion as compared to OT 
administration exclusively at reperfusion.  
 
IV.2.3. The protection induced by OT is mediated by OTR 
OT is almost identical to a second neurohypophyseal hormone, arginine vasopressin (AVP), 
differing from it by only 2 amino acid residues. Conceivably both hormones can act through 
both receptors, with different affinities. Based on the results obtained using an antagonist 
specific to OTR, OTA, we demonstrate that OT is cardioprotective if its signaling is 
mediated by OTR. OTR expression is down-regulated in hearts having undergone cardiac 
ischemia by 40-50%73,74, and this reduction could be restored by treatment with OT74. 
Interestingly exercise training increased OTR mRNA expression by 4-6 times in both sham-
operated and ovariectomized rat hearts, pointing to a possible involvement of OT signaling in 
the cardioprotective effects of exercise72. 
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IV.2.3.1. OTR knockdown reverses the protective pattern seen by OT treatment 
H9c2 cells treated with scrambled (non-silencing) siRNA sequences displayed an increase in 
cell death upon IR that was significantly attenuated upon treatment with OT at reperfusion. 
In the absence of OTR, IR in itself caused a more modest induction of cell death, and 
treatment with OT at reperfusion caused an increase in the number of TUNEL-positive nuclei 
compared to untreated cells. This suggests the possibility that in the absence of OTR, OT can 
trigger deleterious signaling via the related V1a and/or V2 receptors. This agrees with reports 
that low-dose AVP infusion after 1 hour of ischemia increased mortality and cardiac 
dysfunction in mice73, and that cardiac-restricted over expression of V1a causes left 
ventricular dysfunction118. Furthermore, the use of an antagonist for AVP receptors V1a and 
V2 in itself proved to be protective in our model of simulated ischemia - reperfusion. We 
would thus expect that AVP signaling is deleterious in this context, and OT is favourable. 
However, treatment with AVP did not decrease cardiomyocyte viability at concentrations 
ranging from 0.1 to 100 nM, but improved viability at a concentration of 1000 nM. The 
protection elicited by the high concentration of AVP may reflect the fact that at higher 
concentrations AVP can trigger signaling via OTR. Similarly, reduced protection was 
observed when OT was administered at concentrations higher than 500 nM, suggesting that 
at high concentrations OT may trigger signaling via V1a. 
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IV.3. Mechanisms of OT - induced cardiomyocyte protection 
IV.3.1. OT prevents the intracellular formation of reactive oxygen species 
after 1 and 2 hours of reperfusion 
The formation and sustained opening of the mitochondrial permeability transition pore 
(mPTP) is considered the irreversible commitment of a cell to death11. Among the stimuli 
known to trigger its opening is the excess formation of reactive oxygen species within the 
cell, leading to oxidative stress8,10,11. It is believed that the reintroduction of oxygen into  
altered mitochondria (i.e., with high matrix Ca2+ and inorganic phosphate concentrations) at 
reperfusion causes an excessive production of ROS, leading to intracellular oxidative stress, 
which under the high Ca2+ concentrations causes death through opening of the mPTP8. This 
study demonstrated that when OT is administered at reperfusion, there is a 30 % decrease in 
intracellular ROS content after 2 hours of reperfusion.  
 
IV.3.2. OT treatment under normoxic conditions causes a short - lived 
burst in ROS production 
A short treatment with OT under normal conditions (i.e. not after ischemia - reperfusion) 
caused up to a 25% increase in ROS that was apparent after 5 and 15 but not 30 minutes of 
treatment with OT. This observation agrees with the proposed mechanism by which 
cardioprotective stimuli prevent mPTP formation, stating that protein kinase C-ε becomes 
activated by a burst of ROS production and subsequently inhibits the opening of the mPTP14. 
In this model, cardioprotective stimuli, such as bradykinin, opioids, natriuretic peptides and 
IPC19, are believed to cause the opening of mitochondrial ATP-sensitive K+ channels, which 
trigger a burst in ROS, and this ROS is the signal that is transmitted to PKCε, and PKCε then 
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inhibits mPTP opening by unclear mechanisms14. The exogenous administration of H2O2 can 
in itself prevent mPTP formation14. Some authors have proposed that H2O2 treatment can act 
as a preconditioning stimuli because it causes a transient opening of mPTP which reduces 
mitochondrial ions and prevents the prolonged opening of the mPTP, which would be 
lethal119. Some authors have proposed that ligand triggers (such as adenosine, bradykinin and 
opioids) of pre- and postconditioning may generate a burst in ROS production that protect 
against the subsequent and more substantial generation of injury producing ROS during 
reperfusion20. The ROS scavenger N-acetylcysteine (NAC) blocks the cardioprotection 
induced by PC if administered in the first 3 minutes of reperfusion8. A recent report 
demonstrated that NAC abolished the protective effect of OT preconditioning in the 
anesthetized rat heart undergoing MI81. This observation agrees with our data that OT 
treatment in normoxia causes a short-lived ROS production, whereas OT administration at 
reperfusion causes a decrease in intracellular ROS generation after 1 and 2 hours of 
reperfusion. 
 
IV.3.3. OT protects from doxorubicin - induced mitochondrial toxicity 
The modulation in ROS production and the importance of mitochondria in cell death and 
survival decisions prompted us to investigate whether OT could directly protect 
mitochondrial function of cardiomyocytes. Doxorubicin is a commonly used 
chemotherapeutic agent for the treatment of neoplasms. However, its use is limited due to the 
fact that it causes major cardiac toxicity through mitochondrial dysfunction and caspase-3 
activation113 that is likely to be different from the antitumor mechanism116. Here we report 
that a 30 minute pre-treatment with OT (62.5 and 1000 nM) prior to the administration of 
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Dox for 24 hr resulted in improved viability of H9c2 cells. Our observations demonstrating 
that OT treatment of cardiomyocytes stimulates Akt phosphorylation and translocation into 
mitochondria is consistent with some mechanisms of protection against Dox-induced cardiac 
toxicity which include the increase in phosphorylated Akt and attenuation of Dox-induced 
oxidative stress116. 
 
IV.4. Signalisation involved in OT-mediated cardiomyocyte 
protection 
IV.4.1. Pi3K/Akt signaling 
GPCR are known to activate the Pi3K-Akt pathway, a major pro-survival pathway important 
in survival from ischemia - reperfusion injury, and OT-OTR signaling has been shown to 
involve Pi3K-Akt76,112. Furthermore, protection from Dox-induced cardiotoxicity by heat 
shock protein (Hsp) 20 involves  Akt  phosphorylation 116. Wortmannin is a metabolite of the 
fungus Penicillum funiculosum and a potent inhibitor of Pi3Ks; Pi3Ks activate 
phosphorylation of Akt. Wortmannin concentrations of 100 and 1000 nM completely 
abrogated the protection induced by OT in a concentration - dependent manner without 
causing cell toxicity. This finding indicates that the protection induced by OT is mediated by 
the action of Pi3Ks, the kinase which also mediates glucose uptake in isolated neonatal rat 
cardiomyocyte culture76. 
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IV.4.2. OT causes phosphorylated Akt (Thr308) to co-localize with 
mitochondria in or around the nucleus 
Using formazan production for the measurement of cell viability and metabolic activity, a 
significant cellular protection was observed at a concentration of 1 nM of OT, with an 
optimal protection at 62.5-125 nM. This observation is consistent with a report by Klein et al. 
on Caco 2BB gut cells demonstrating that OT activates the Pi3K pathway maximally when 
given at a concentration of 62.5 nM. In our study, treatment of H9c2 cells with this 
concentration of OT resulted in the formation of clear intracellular structures of accumulated 
p-Akt. Confocal microscopy analysis revealed that these structures of p-Akt co-localize 
precisely with mitochondrial protein Cox IV.  
Cardioprotective stimuli that open mitoKATP channels such as BMS-191095 are thought to 
trigger mitoKATP opening via the translocation of phosphorylated Akt to the mitochondria36.  
Activated mitochondrial Akt phosphorylates hexokinase-II and results in the prevention of 
mPTP opening due to ROS and Ca2+ overload38. Akt is also known to phosphorylate Bcl-2 
family members: BAD phosphorylation at Ser136 by Akt is cardioprotective, and Bax 
phosphorylation at Ser184 by Akt prevents the conformational change necessary for Bax 
translocation to the mitochondria35 where it triggers mPTP opening. Additionally, Akt causes 
the inhibition of the translocation of apoptosis initiating factor (AIF) to the nucleus where it 
induces DNA fragmentation; Akt also phosphorylates and inactivates caspase-9 (Ser 196)30. 
Activated Akt is known to be translocated actively to the nucleus, where it acts to regulate 
gene transcription by phosphorylating many different targets such as Forkhead transcription 
factors (FOXO), CREB120 and Pim-1 kinase121. In the context of cardiac ischemia, nuclear 
Akt has been shown to be cardioprotective in hypoxia and ischemia-reperfusion 122.  
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Constitutive and sustained Akt activation is associated with cardiomyocyte hypertrophy28, 
nuclear-targeted Akt does not induce hypertrophy in cardiomyocytes in vivo and in vitro122 
but rather antagonizes hypertrophy and causes an increase in atrial natriuretic peptide (ANP) 
expression123. Oxytocin is well known to cause an increase in ANP expression and release 
from the heart63. It is thus possible that the mechanism by which OT exerts its protection 
during reperfusion involves Akt phosphorylation and translocation to the nucleus, where it 
causes an increase in protective ANP synthesis and release. Our experiments supported this 
concept by the demonstration that the use of ANP receptor antagonist, A71915 resulted in the 
loss of OT-mediated protection of H9c2 cells exposed to IR.  Although de novo ANP 
synthesis are unlikely to play a role in the acute phase of ischemia - reperfusion injury, ANP 
release from intracellular stores is a fast process counted in seconds and minutes. 
Furthermore, ANP release, known to be triggered in cardiomyocytes by the action of OT63, 
also causes nuclear accumulation of phosphorylated Akt and pro-survival signaling31. ANP is 
an established cardioprotective agent124; it inhibits the release of renin and aldosterone 
synthesis, inhibits sympathetic nerve activity, ameliorates endothelial function, decreases 
fibrosis, inflammation and apoptosis in myocytes secondary to cGMP production89. 
 
IV.4.3. OT mediates cardioprotection through eNOS phosphorylation and 
cGMP-PKG signaling 
The activity of cGMP - dependent protein kinase (PKG) is well - known to trigger protective 
signaling in the context of myocardial ischemia - reperfusion injury. PKG can directly 
prevent mPTP opening, possibly due to the opening of mitoKATP and PKCε - mediated 
inhibition of the mPTP. The protective effect of preconditioning with oxytocin was abrogated 
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by the administration of 5-hydroxydecanoate, an inhibitor of mitoKATP in anesthetized rat80 
and rabbit82 hearts. Oxytocin could trigger PKG signaling by three different mechanisms. 
First, OT acting via OTR stimulates PLC-β to produce inositol-3,4,5-triphosphate (IP3) and 
DAG. IP3 leads to Ca2+ release from intracellular stores and the activation of Ca-Calmodulin 
(CaM), which activates eNOS to increase NO production. Secondly, OTR stimulates Pi3K 
activity to produce phosphatidylinositol-3,4,5-triphosphate (PIP3), which activates Akt 
signaling and in turn eNOS activity. NO produced from these two pathways stimulates 
soluble guanylate cyclase (sGC) to produce cGMP, which activates PKG125. Thirdly, as 
mentioned above, OT stimulates ANP release from intracellular stores via OTR-mediated 
Ca2+ mobilization secondary also to PLC production of IP3. ANP in turn increases cGMP 
production via natriuretic peptide receptor A (NPR-A), a membrane-bound guanylyl cyclase 
(pGC). 
NO production has also been proposed as cardioprotective due to the attenuation of ROS 
production during reperfusion caused by the reversible inhibition of mitochondrial 
respiratory complex I by S-nitrosylation19. Phosphorylation of eNOS at Ser1177, which is 
protective in ischemia - reperfusion45, is mediated by Akt126. Recent evidence indicates that 
the subcellular localization of eNOS is an important component in the regulation of the effect 
induced by NO127, and vascular endothelial growth factor (VEGF) stimulation was shown to 
induce translocation of activated eNOS to the nucleus of vascular endothelial cells128. OT 
treatment has been shown to trigger NO production in stem cells129, with increased eNOS 
expression in the peri-infarct area in rat MI following OT preconditioning74 and increased 
eNOS phosphorylation in rabbits receiving OT at reperfusion71. Similarly, the protective 
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effect of OT preconditioning was abolished by the administration of L-NAME, a non-
specific NOS inhibitor, in both anesthetized rat81 and rabbit82 hearts.  
 
Figure 30. Proposed protective signaling triggered by OT in cardiomyocytes.  OT acts 
via OTR, a sarcolemmal GPCR. The signal stimulates PLC-β and Pi3K/Akt pathways, which 
result in NO production and the modulation of ionic pump activity, resulting in the inhibition 
of mitochondrial permeability transition pore (mPTP) opening. OT also causes ANP release, 
which also causes cGMP production (through NPR-A) and cytoprotection. 1. NHE: Na+/H+ 
exchanger; 2. ATP-dependent Na+/K+ pump;  3. Na+/bicarbonate co-transporter; 4. NCE: 
Na+/Ca2+ exchanger. OT: oxytocin; OTR: OT Receptor; PLC-β: phospholipase C type β; 
DAG: diacylglycerol; IP3: inositol-3-phosphate; PKC: protein kinase C; Erk1/2 : 
extracellular-regulated kinases 1 and 2; PI3K phosphatidylinositol-3-kinase; eNOS: 
endothelial nitric oxide synthase; NO: nitric oxide; sGC: soluble guanylate cyclase; pGC: 
particulate guanylate cyclase; cGMP: cyclic guanosine monophosphate; PKG: cGMP-
OTR
PI3K
Akt
eNOS
sGC PKG
ANP
NO
mitoKATP
PLC-β
PKCErk 1/2
OT
Respiratory Complex I
ROS
cGMP
Cell Death
PKC-ε
↑[H+]
Anaerobic Metabolism
H+
Na+
↑[Na+]
↑[Ca2+]
Ca2+ overload
Hypercontractility
Na+
K+
AMPK
Ischemia
↑[AMP]/[ATP]
Ca2+
CaMKK
DAG IP3
ANP 
NPR-A
pGC
Gαq11
mPTP
ATP
1
Na+
Ca2+
ROS
Na+- HCO3
Na+
Na+
EXTRACELLULAR
Wortmannin
ODQ KT5823
A71915
(-)
100 
 
 
dependent protein kinase; ROS: reactive oxidative species; mPTP: mitochondrial 
permeability transition pore; mitoKATP: mitochondrial ATP-sensitive K+ channels; CaM: 
Ca2+- Calmodulin; CaMKK: CaM kinase kinase; AMPK: AMP-activated protein kinase; 
NPR-A:  natriuretic peptide receptor type A. Adapted from Ref. 130  
 
IV.5. Signalosome hypothesis  
Signalosomes have recently been discovered as cardioprotective signaling complexes 
induced upon GPCR activation and pre- and postconditioning stimuli51,52. Based on our 
observations, we propose that OT stimulation triggers the formation of signalosomes. The 
basis for this comes from the observed co-localization of phosphorylated Akt with 
mitochondrial proteins as well as with the phosphorylated (Ser1177) form of eNOS in precise 
intracellular structures.  The existence of these complexes may explain the co-localization of 
phosphorylated Akt with the mitochondria as well as with phosphorylated eNOS, and the 
formation of the observed intracellular structures. Indeed, the effect of signalosomes can be 
blocked by the administration of an inhibitor of PKG, KT-582351; the same inhibitor 
completely blocks the OT - mediated protection of cardiomyocyte viability observed in our 
experiments. Furthermore, eNOS and OTR are both well-known to associate with caveolins 
(integral membrane proteins that define the structure of caveolae131), and the cardioprotective 
effect of eNOS can be blocked by chemically disrupting caveolae132, pointing to the need for 
the caveolar signaling platform for eNOS-mediated cardioprotection. Further experiments are 
necessary to determine whether OT treatment causes protective signalosome formation. Such 
experiments might include the isolation of these structures by ultracentrifugation as well as 
immunoprecipitation of caveolar structures. 
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Figure 31. OTR signalosome hypothesis. Upon OT stimulation, a caveolar assembly 
containing OTR, p-Akt and p-eNOS is formed, which migrates to cell's mitochondria and 
causes mitoKATP opening. 
 
Overall, OT is emerging as an exciting candidate for cardioprotection at the time of 
reperfusion. Repeated observations of the cardioprotection induced by OT in vivo as well as 
in vitro, along with a more detailed mechanistic analysis presented in this thesis point to a 
great potential of this hormone for clinical use. Further potential advantages of OT 
administration to MI patients include the reduction in stress-induced cardiovascular 
responses following MI in rats133, the observation that OT induces  cardiomyogenesis of 
mouse embryonic stem cells through an NO-dependent mechanism134 as well as of adult sca-
1-positive stem cells135 prevents cardiac hypertrophy (A. Menaouar, unpublished results) and 
enhances the protective potential of mesenchymal stem cells114. 
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V. CONCLUSIONS 
The results presented in this thesis clearly indicate that oxytocin (OT) directly triggers protective 
signaling in cardiomyocytes exposed to simulated ischemia - reperfusion through signaling via 
oxytocin receptor. Furthermore, the loss of OT receptor expression results in increased cell death 
following treatment with OT, indicating that the expression level of OTR is a critical determinant 
of the effect elicited by OT. It is possible that in the absence of OTR, deleterious signaling 
proceeds via vasopressin receptors present on cardiomyocytes. While OT and OTR knockout 
mice present slightly altered cardiovascular regulation, to our knowledge no studies have 
addressed the implications of OT or OTR deficiency in cardiac salvage following ischemia - 
reperfusion injury. New experiments must be carried out in these knockout models to determine 
the effects of OT signaling in the absence of OTR in the context of cardiac ischemia - 
reperfusion.  
Oxytocin exerts an optimal protective effect in simulated ischemia - reperfusion (IR) if 
administered exclusively at the onset of reperfusion, as a postconditioning stimulus. This may 
reflect the fact that OTR desensitization causes an attenuated response to OT signaling at the 
critical moment of early reperfusion. 
The protection of mitochondrial integrity in early reperfusion is critical for cell survival. 
Supporting a role for OT protection of mitochondrial integrity is the observation that oxytocin 
preconditioning protects cardiomyocytes against doxorubicin - induced mitochondrial toxicity in 
a concentration - dependent manner. 
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Oxytocin treatment of cardiomyocytes results in Akt and eNOS phosphorylation and their 
translocations to the cells' nuclei. Additionally, upon oxytocin treatment, the phosphorylated 
form of Akt co-localizes with cell mitochondria and generates specific structures within or 
around cell nuclei. To our knowledge this is the first report describing the formation of these 
structures. Their significance in cardioprotective signaling remains to be further studied. 
Based on data obtained from the use of specific inhibitors, we can conclude that the protection 
induced by oxytocin to cardiomyocytes undergoing IR requires signaling through Pi3K-Akt, the 
generation of cGMP through particulate, and the activation soluble guanylate cyclase cGMP 
dependent protein kinase (PKG). 
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